<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anesthesia for electroconvulsive therapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anesthesia for electroconvulsive therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Anesthesia for electroconvulsive therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adrian W Gelb, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Oana Maties, MD, MRCP, FRCA</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Girish P Joshi, MB, BS, MD, FFARCSI</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephanie B Jones, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Nussmeier, MD, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4018483525"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Electroconvulsive therapy (ECT), which involves passing a small brief current through the brain to induce a generalized seizure, is performed under general anesthesia. ECT is primarily used to treat severe depression, but is also indicated for selected patients with other conditions including bipolar disorder, schizophrenia, schizoaffective disorder, catatonia, and neuroleptic malignant syndrome.</p><p>This topic will review anesthetic management for patients undergoing an ECT procedure. A separate topic addresses medical consultation and strategies to reduce risk before and after ECT. (See  <a class="medical medical_review" href="/z/d/html/4817.html" rel="external">"Medical evaluation for electroconvulsive therapy"</a>.)</p><p>Discussions of the technique, efficacy, and indications for performing ECT are found in other topics:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1712.html" rel="external">"Technique for performing electroconvulsive therapy (ECT) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1709.html" rel="external">"Overview of electroconvulsive therapy (ECT) for adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1711.html" rel="external">"Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)"</a> and  <a class="medical medical_review" href="/z/d/html/14659.html" rel="external">"Bipolar disorder in adults: Indications for and efficacy of electroconvulsive therapy"</a>.)</p><p></p><p class="headingAnchor" id="H4211967207"><span class="h1">TECHNICAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H2142531781"><span class="h2">Procedural location</span><span class="headingEndMark"> — </span>Depending on institutional preferences, ECT is performed under general anesthesia in a variety of offsite or remote locations, including the post-anesthesia care unit (PACU), preoperative procedural areas, or a dedicated suite for ECT. As with all locations that serve patients receiving general anesthesia, the standards set by the American Society of Anesthesiologists (ASA) for provision of anesthetic care and monitoring should be met [<a href="#rid1">1</a>]. Equipment to manage emergencies (eg, cardiac arrest, difficult airway, malignant hyperthermia) should be readily available.</p><p class="headingAnchor" id="H4207113348"><span class="h2">Standard preparations</span><span class="headingEndMark"> — </span>Standard preparations for a general anesthetic are necessary, including checkout of the anesthesia machine, if present, and preparation of routinely administered anesthetic and adjuvant drugs, as well as equipment for advanced airway management. (See  <a class="medical medical_review" href="/z/d/html/94135.html" rel="external">"Induction of general anesthesia: Overview", section on 'Preparation for anesthetic induction'</a>.)</p><p>Since ECT is administrated under general anesthesia, standard American Society of Anesthesiologists (ASA) monitoring is necessary for these procedures [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/100067.html" rel="external">"Basic patient monitoring during anesthesia", section on 'Standards for monitoring during anesthesia'</a>.)</p><p class="headingAnchor" id="H1147871708"><span class="h2">Procedural techniques</span></p><p class="bulletIndent1"><span class="glyph">●</span>Scalp electrode placement – Scalp electrode placement for ECT is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1712.html" rel="external">"Technique for performing electroconvulsive therapy (ECT) in adults", section on 'Electrode placement'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrical stimulus – Electrical stimulus type and dose for inducing a seizure are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1712.html" rel="external">"Technique for performing electroconvulsive therapy (ECT) in adults", section on 'Stimulus type'</a> and  <a class="medical medical_review" href="/z/d/html/1712.html" rel="external">"Technique for performing electroconvulsive therapy (ECT) in adults", section on 'Stimulus dose'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Novel seizure therapies – Novel seizure therapies have been designed to increase spatial precision and avoid stimulating the deep brain structures involved in memory retention (eg, the hippocampus), to lessen neurocognitive side effects [<a href="#rid3">3</a>]. Examples include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individualized low amplitude seizure therapy (iLAST), which aims to reduce spread of current in the brain by titrating current amplitude during seizure titration.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Magnetic seizure therapy (MST), which involves the use of transcranial magnetic stimulation (TMS) to better control spatial distribution and extent of stimulation [<a href="#rid4">4</a>].</p><p></p><p class="headingAnchor" id="H836886909"><span class="h1">PREANESTHETIC ASSESSMENT AND MANAGEMENT</span></p><p class="headingAnchor" id="H2475099226"><span class="h2">Medical evaluation and risk reduction</span><span class="headingEndMark"> — </span>Psychiatrists often request a medical evaluation before scheduling ECT since many eligible patients are older adults with multiple medical comorbidities. In addition to American Society of Anesthesiologists (ASA) Class IV or V status  (<a class="graphic graphic_table graphicRef87504" href="/z/d/graphic/87504.html" rel="external">table 1</a>), the American Psychiatric Association notes that the following conditions are associated with increased risk [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Unstable or severe cardiovascular disease</p><p class="bulletIndent1"><span class="glyph">●</span>Space-occupying intracranial lesion with evidence of elevated intracranial pressure</p><p class="bulletIndent1"><span class="glyph">●</span>Recent cerebral hemorrhage or stroke</p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding or otherwise unstable vascular aneurysm</p><p class="bulletIndent1"><span class="glyph">●</span>Severe pulmonary condition</p><p></p><p>The medical consultation is reviewed by the anesthesiologist to ensure knowledge of the presence of medical comorbidities, proposed strategies to reduce risk, and recommended treatments for complications after the procedure [<a href="#rid6">6</a>]. In particular, identification of patients at risk of cardiovascular complications is necessary for decisions regarding pre-emptive administration of beta blockers or other agents to minimize tachycardia and hypertension that typically occurs due to sympathetic responses to seizure induction. (See <a class="local">'Sympathetic responses'</a> below and  <a class="medical medical_review" href="/z/d/html/4817.html" rel="external">"Medical evaluation for electroconvulsive therapy", section on 'Cardiovascular effects'</a>.)</p><p>ECT is considered to be generally safe in pregnant patients [<a href="#rid7">7,8</a>]. Modifications in procedural techniques and use of perianesthetic agents are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1712.html" rel="external">"Technique for performing electroconvulsive therapy (ECT) in adults", section on 'Pregnancy'</a>.)</p><p>Additional information regarding medical and preanesthetic evaluation is available in separate topics. (See  <a class="medical medical_review" href="/z/d/html/4817.html" rel="external">"Medical evaluation for electroconvulsive therapy"</a> and  <a class="medical medical_review" href="/z/d/html/94539.html" rel="external">"Preoperative evaluation for anesthesia for noncardiac surgery"</a>.)</p><p class="headingAnchor" id="H832107483"><span class="h2">Management of cardiac and noncardiac implantable electronic devices</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pacemakers and implantable cardioverter-defibrillators</strong> – Management of a patient with a cardiac implantable electronic device (CIED) such as a pacemaker or implantable cardioverter-defibrillator (ICD) is similar to that for other surgical procedures where electromagnetic interference is likely [<a href="#rid6">6</a>]. In patients who are <strong>not</strong> pacing-dependent, placing a magnet over the pulse generator of the pacemaker (to put it in an asynchronous mode) or the ICD (to suspend tachyarrhythmia detection and therapy) is safe, convenient, and reliable. In pacing-dependent patients with a pacemaker or ICD, consultation with the cardiology or institutional CIED care team is necessary to reprogram the device before and after the procedure.</p><p></p><p class="bulletIndent1">Further details are available in a separate topic. (See  <a class="medical medical_review" href="/z/d/html/94293.html" rel="external">"Perioperative management of patients with a pacemaker or implantable cardioverter-defibrillator"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deep brain stimulators</strong> – Although most manufactures of implantable electronic medical devices recommend not using ECT in patients with functioning devices in the head or neck, some patients with a deep brain stimulator (DBS) device are also being treated with ECT [<a href="#rid6">6,9,10</a>].</p><p></p><p class="bulletIndent1">Concerns regarding this select group of patients include heating of the DBS electrodes during application of the electrical stimulus or movement of these electrodes due to seizure-induced motor activity [<a href="#rid9">9</a>], although none of these adverse effects have been reported in patients with DBS undergoing ECT. Periprocedural management of the DBS device is done in consultation with the neurosurgical team and the device manufacturer, and may vary among centers. Some stop DBS therapy throughout the complete course of treatment, while others temporarily disable the DBS device before each procedure, with resumption of therapy immediately after each procedure [<a href="#rid11">11</a>].</p><p></p><p class="headingAnchor" id="H2587869438"><span class="h2">Management of chronically administered medications</span></p><p class="headingAnchor" id="H457685564"><span class="h3">Psychotropic medications: Anesthetic considerations</span><span class="headingEndMark"> — </span>Patients presenting for ECT are often taking multiple psychotropic medications for treatment of depression and/or other psychiatric illness. Many psychotropic medications have synergistic effects with ECT and are usually continued during the periprocedural period without compromising safety (eg, most antidepressants, antipsychotics, and <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>). The patient’s morning dose is administered on the same day of the procedure, shortly after recovery from general anesthesia has occurred. (See  <a class="medical medical_review" href="/z/d/html/1709.html" rel="external">"Overview of electroconvulsive therapy (ECT) for adults", section on 'Psychotropic drugs'</a>.)</p><p></p><p>However, some psychotropic agents have potentially dangerous interactions with medications that are routinely administered during anesthetic care. Familiarity with such interactions is necessary to recognize and appropriately treat common as well as rare but serious adverse effects.</p><p>Recommendations for psychotropic medications that patients undergoing ECT may be taking include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antidepressants</strong> – Antidepressants can improve the efficacy of ECT, and are generally safe to continue during the periprocedural period.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Selective serotonin reuptake inhibitors </strong>– Selective serotonin reuptake inhibitor (SSRI) agents such as <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>, <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, and <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> are the most commonly used antidepressants for treatment of mild to moderate depression. These agents are usually continued throughout the periprocedural period; stopping these agents can exacerbate mood and other disorders. These drugs block reuptake of serotonin at the presynaptic membrane. Since they have relatively little effect on the adrenergic, cholinergic, and histaminergic systems there are few associated side effects. (See  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Selective serotonin reuptake inhibitors'</a>.)</p><p></p><p class="bulletIndent2">Potentially important effects of SSRIs during ECT include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Effects on anesthetic agents and adjuvants – <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">Fluoxetine</a> and <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> are inhibitors of cholinesterase in human serum and the erythrocyte membrane. This effect may lead to an extended duration of action for <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a> [<a href="#rid12">12</a>]. Fluoxetine is a potent inhibitor of CYP2D6, and may increase the plasma concentration of agents that rely on hepatic metabolism (eg, antiarrhythmics, antiemetics) [<a href="#rid13">13,14</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Development of serotonin syndrome – Serotonin syndrome is a rare but potentially lethal toxicity characterized by agitation, clonus, hyperreflexia, and hyperthermia. This syndrome may occur in patients taking SSRIs if other drugs with serotoninergic potential are administered during the perianesthetic period (eg, <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> [<a href="#rid15">15,16</a>], <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> [<a href="#rid17">17</a>], or <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> and other opiates [<a href="#rid15">15,17-19</a>]). Thus, the anesthesiologist should be familiar with signs and symptoms of serotonin syndrome, emergency treatment  (<a class="graphic graphic_table graphicRef73400" href="/z/d/graphic/73400.html" rel="external">table 2</a>), and potential complications (metabolic acidosis, rhabdomyolysis, seizures, renal failure, disseminated intravascular coagulation [DIC], coma) of serotonin syndrome [<a href="#rid17">17,20</a>]. (See  <a class="medical medical_review" href="/z/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Selective norepinephrine reuptake inhibitors</strong> – Selective norepinephrine reuptake inhibitor (SNRI) agents (eg, <a class="drug drug_general" data-topicid="8944" href="/z/d/drug information/8944.html" rel="external">desvenlafaxine</a>, <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a>, <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>, <a class="drug drug_general" data-topicid="90236" href="/z/d/drug information/90236.html" rel="external">levomilnacipran</a>, <a class="drug drug_general" data-topicid="9506" href="/z/d/drug information/9506.html" rel="external">milnacipran</a>) treat depression by initially blocking presynaptic serotonin and norepinephrine transporter proteins. Considerations regarding continuation of SNRIs during the periprocedural period are similar to those with SSRIs, although there are limited specific data for SNRIs. (See  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Selective serotonin reuptake inhibitors'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tricyclic antidepressants </strong>– Tricyclic antidepressant agents (TCAs) such as <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a>, <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a>, dosulepin, <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">imipramine</a>, and <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">desipramine</a> inhibit the presynaptic reuptake of serotonin and norepinephrine. They also have antimuscarinic, antihistaminergic, and anti-alpha-1 adrenergic effects. These agents are usually continued throughout the periprocedural period to avoid worsening of depression. Abrupt withdrawal of tricyclic antidepressants should be avoided as this can lead to insomnia, nausea, headache, increased salivation, and sweating [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Tricyclic and tetracyclic antidepressants'</a>.)</p><p></p><p class="bulletIndent2">Potentially important effects of TCAs during ECT include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Interaction with vasopressor agents – Since TCAs inhibit the uptake of norepinephrine and serotonin at the synaptic cleft, they can potentiate the vasopressor effects of indirect sympathomimetic agents such as <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">ephedrine</a> or metaraminol, and may also amplify the effects of catecholamines (eg, <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, norepinephrine).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Interaction with other drugs – The anticholinergic side effects of TCAs can be accentuated by administration of anticholinergic medications such as <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> or <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">scopolamine</a> during the periprocedural period, with increased likelihood of postoperative delirium. Also, <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">tramadol</a> and <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a> are avoided due to additive serotoninergic effects. (See  <a class="medical medical_review" href="/z/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Effects on the electrocardiogram – Electrocardiographic (ECG) effects include prolongation of the QTc interval (the QT interval that is corrected for heart rate), widening of the QRS complex, and conduction delays.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Other effects – Other common side effects include postural hypotension, delayed gastric emptying, urinary retention, dry mouth, blurred vision, and sedation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monoamine oxidase inhibitors </strong>– The monoamine oxidase inhibitors (MAOIs) target the monoamine oxidase (MAO) enzymes responsible for the breakdown of amine neurotransmitters (norepinephrine and serotonin). MAOIs are usually continued during the periprocedural period, particularly when the psychiatrist believes temporary withdrawal of the agent will exacerbate or precipitate a depressive syndrome. (See  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Monoamine oxidase inhibitors'</a>.)</p><p></p><p class="bulletIndent2">Potentially important effects of MAOIs during ECT include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Interaction with vasopressor agents – Use of indirect sympathomimetic agents such as <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">ephedrine</a> or metaraminol is contraindicated since their metabolism is inhibited by MAOIs with consequent risk of an exaggerated vasopressor effect (eg, severe hypertension). Direct-acting catecholamines (<a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, norepinephrine) or vasopressor agents (eg, <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a>, <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a>) can be used safely if slowly and carefully titrated.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Interaction with other drugs – Administration of <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a> or pethidine is avoided, as interactions with these drugs may precipitate a serotoninergic reaction. (See  <a class="medical medical_review" href="/z/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p></p><p class="bulletIndent3"><a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">Remifentanil</a>, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a>, and <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> can be safely used in patients taking MAOIs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mood stabilizers</strong> – Mood stabilizers include <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> and the anticonvulsants <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, and <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lithium</strong> – Typically, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> levels are reduced below the full therapeutic range at the time of each ECT treatment by withholding one or two doses prior to the treatment [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Mood stabilizing agents (lithium and valproate)'</a>.)</p><p></p><p class="bulletIndent2">Potentially important effects of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> during ECT include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Effects on procedural outcome – <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">Lithium</a> has the potential to increase the adverse cognitive effects of ECT.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Effects on anesthetic agents and adjuvants – <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">Lithium</a> may prolong the effects of <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a> (which is typically used during ECT to reduce tonic-clonic movements (see <a class="local">'Neuromuscular blocking agents'</a> below)) [<a href="#rid23">23,24</a>], as well as the effects of nondepolarizing neuromuscular blocking agents (NMBAs) [<a href="#rid25">25</a>]. However, these problems are not clinically significant in most cases [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anticonvulsant mood stabilizers (</strong><a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a><strong>, </strong><a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a><strong>)</strong> – Most patients taking anticonvulsants such as carbamazepine and valproate for mood stabilization undergo successful treatment with ECT by withholding the drug on the evening before the procedure, rather than discontinuing it [<a href="#rid26">26</a>]. However, patients taking anticonvulsants for epilepsy should continue these drugs throughout the perioperative period if possible. (See  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Mood stabilizing agents (lithium and valproate)'</a> and  <a class="medical medical_review" href="/z/d/html/4817.html" rel="external">"Medical evaluation for electroconvulsive therapy", section on 'Epilepsy'</a>.)</p><p></p><p class="bulletIndent2">Potentially important effects of anticonvulsant mood stabilizers during ECT include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Effects on seizures – Anticonvulsant mood stabilizers may impact seizure induction or duration during ECT, although the effect is not consistent [<a href="#rid27">27</a>]. In one randomized trial, full dosing of anticonvulsant therapy (either <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>) before a bilateral course of ECT was not associated with differences in induction or seizures or adverse cognitive outcomes compared with half dosing or discontinuation of anticonvulsant [<a href="#rid28">28</a>]. However, if seizures have been difficult to elicit or too short during previous ECT procedures in an individual patient, then the anticonvulsant is withheld on the evening before an ECT procedure [<a href="#rid29">29</a>]. In some cases, the dose is also reduced during the course of ECT treatment.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Effects on anesthetic agents and adjuvants – <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">Carbamazepine</a> is a potent inducer of the cytochrome P450 3A4 enzyme system. Thus, it may increase anesthetic requirements and/or prolong the duration of action of <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a> [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Other effects – In rare cases, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproic acid</a> has been associated with perioperative hyperammonemia [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/338.html" rel="external">"Valproic acid poisoning", section on 'Hyperammonemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antipsychotics</strong> – Antipsychotic agents include <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a>, <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">thioridazine</a>, <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">perphenazine</a>, and <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a>. These agents are well-tolerated during ECT and are typically continued throughout the periprocedural period since they may provide a synergistic antipsychotic effect [<a href="#rid32">32</a>]. In fact, ECT has been used in combination with clozapine for treatment-resistant schizophrenia [<a href="#rid33">33,34</a>].</p><p></p><p class="bulletIndent1">Potentially important effects of antipsychotic agents during ECT include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Effects on anesthetic agents and adjuvants – Antipsychotics may enhance the effects of central nervous system (CNS) depressants, thereby lowering anesthetic dose requirements [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Effects on beta blocking agents – Antipsychotics have selectivity for the CYP2D6 isoform, which primarily metabolizes beta blockers. Thus, the efficacy of beta blocker use to treat hypertension and tachycardia during ECT may be altered [<a href="#rid35">35</a>]. (See <a class="local">'Sympathetic responses'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other common side effects – All antipsychotic agents are associated with an increased risk of extrapyramidal syndromes (eg, akathisia, tardive dyskinesia, parkinsonian tremor).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other rare side effects – A rare (incidence between 0.02 and 3.23 percent [<a href="#rid36">36</a>]) but life-threatening side effect of antipsychotic agents is neuroleptic malignant syndrome (NMS). It is characterized by hyperthermia, muscle rigidity, autonomic instability (diaphoresis, labile blood pressure), and mental status changes (agitation, delirium, or coma) that last for hours to weeks. Complications of NMS can include myoglobinuria, renal failure, cardiac failure, disseminated intravascular coagulation, pulmonary embolus, and cognitive sequelae caused by hypoxemia and prolonged hyperthermia [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">"Neuroleptic malignant syndrome"</a>.)</p><p></p><p class="bulletIndent2">Some antipsychotic drugs have been linked with cardiomyopathy and myocarditis [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benzodiazepines</strong> – Benzodiazepines have anxiolytic, sedative, anticonvulsant, and antinociceptive effects [<a href="#rid39">39</a>]. Chronically administered benzodiazepines (eg, <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a>, <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">alprazolam</a>, <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a>, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>) are typically tapered and discontinued before a planned ECT procedure. Furthermore, administration of short-acting benzodiazepines such as <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a> is avoided before performing an ECT procedure.</p><p></p><p class="bulletIndent1">Potentially important effects of benzodiazepines during ECT include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Effects on seizures – Benzodiazepines are likely to interfere with ECT by impacting seizure induction and decreasing seizure duration. However, results are inconsistent and may be partially dependent on ECT technique [<a href="#rid40">40,41</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Effects on anesthetic agents and adjuvants – Benzodiazepines have synergistic effects with most other anesthetic agents.</p><p></p><p class="headingAnchor" id="H1688329075"><span class="h3">Other chronically administered medications</span><span class="headingEndMark"> — </span>Management of other chronically administered medications is discussed in detail in a separate topic. (See  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management"</a>.)</p><p class="headingAnchor" id="H3119713248"><span class="h2">Preanesthetic medications</span><span class="headingEndMark"> — </span>Preanesthetic medications may be administered in selected patients to prevent or minimize common adverse effects associated with ECT. However, we avoid administration of any benzodiazepine such as <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a> before performing an ECT procedure, due to known anticonvulsant properties that would make seizure induction more difficult.</p><p class="headingAnchor" id="H2662103792"><span class="h3">Headache prophylaxis</span><span class="headingEndMark"> — </span>Headache is the most common adverse effect of ECT, occurring in 26 to 85 percent of patients [<a href="#rid42">42-44</a>]. In a systematic review of post-ECT headache, the weighted mean incidence in patients was 32.8 percent [<a href="#rid45">45</a>]. For those who present with a history of post-ECT headache responsive to over-the-counter analgesics, a prophylactic dose of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> [<a href="#rid46">46</a>], or <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> [<a href="#rid47">47</a>], is often administered before the procedure. A preoperative dose of intravenous (IV) <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">ketorolac</a> 30 mg is an alternative prophylactic agent for patients with a history of severe headaches that are unresponsive to conventional analgesics [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H4198398319"><span class="h3">Nausea prophylaxis</span><span class="headingEndMark"> — </span>Transient post-procedure nausea occurs in approximately 25 percent of patients after ECT [<a href="#rid6">6</a>]. Prophylaxis and/or treatment with IV <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> 4 to 8 mg is reasonable for patients with significant post-ECT nausea. In refractory cases of severe nausea that were not prevented by routine prophylaxis and were resistant to treatment from multiple antiemetics after previous general anesthetics, we typically plan to use <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> as the induction agent.</p><p class="headingAnchor" id="H1142621063"><span class="h3">Anticholinergic administration</span><span class="headingEndMark"> — </span>Severe bradycardia with hypotension may occur during ECT and is most common during the first ECT treatment, when there is a greater chance of administering a subconvulsive stimulus that leads to parasympathetic discharge. Excessive oral and respiratory secretions may also occur due to this parasympathetic response. However, routine prophylaxis with an anticholinergic agent is unnecessary, and undesirable side effects include higher heart rates in patients with ischemic heart disease, memory impairment in older adults, and discomfort due to dry mouth. Furthermore, in one observational study of 32 patients undergoing ECT, <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> significantly reduced the QTc interval, which may be a consideration in patients with risk factors for development of torsades de pointes [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/z/d/html/94357.html" rel="external">"Arrhythmias during anesthesia", section on 'Polymorphic ventricular tachycardia (torsades de pointes)'</a>.)</p><p>In patients with a previous experience of severe bradycardia and/or excessive salivation during ECT, premedication with an IV anticholinergic agent (either <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrrolate</a> 0.2 mg or <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> 0.2 to 0.4 mg) may be beneficial to prevent vagally-mediated bradycardia and asystole, as well as excessive secretions. Low doses of atropine have been shown to result in significantly less bradycardia during ECT, without significant changes in baseline heart rate [<a href="#rid50">50,51</a>]. (See  <a class="medical medical_review" href="/z/d/html/1712.html" rel="external">"Technique for performing electroconvulsive therapy (ECT) in adults", section on 'Cardiovascular medication'</a> and <a class="local">'Parasympathetic responses'</a> below.)</p><p class="headingAnchor" id="H4140585199"><span class="h1">ANESTHETIC MANAGEMENT FOR THE ECT PROCEDURE</span><span class="headingEndMark"> — </span>Choice of anesthetic agents and management of the physiological changes that occur during and shortly after the therapeutic seizure can impact safety, efficacy, and the overall patient experience for an ECT procedure. Good communication between the anesthesiologist and the proceduralist facilitates tailoring a patient-specific anesthetic plan [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H986591288"><span class="h2">Preoxygenation</span><span class="headingEndMark"> — </span>The patient is preoxygenated with supplemental oxygen via nasal cannula or face mask during spontaneous ventilation before induction of general anesthesia, with the goal of maintaining oxygen (O<sub>2</sub>) saturation at or near 100 percent. Adequate preoxygenation improves safety of the ECT procedure compared with spontaneous occurrence of an epileptic seizure. However, O<sub>2</sub> desaturation under 90 percent was noted in 29 percent of ECT procedures in one study, with obesity and seizure duration as the main predictors [<a href="#rid52">52</a>]. (See <a class="local">'Management of oxygenation and ventilation'</a> below.)</p><p class="headingAnchor" id="H888930483"><span class="h2">Choice of induction agent</span><span class="headingEndMark"> — </span>The selected anesthetic agent should not interfere with inducing an effective grand mal seizure. In a large retrospective study of the effects of different doses of anesthetic induction agents, low doses were associated with increased rates of response to ECT [<a href="#rid53">53</a>]. The investigators concluded that deep anesthesia should be avoided during ECT for major depressive disorder to achieve optimal ECT treatment effect.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methohexital</strong> – <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">Methohexital</a> is the induction agent of choice, administered intravenously (IV) at a dose of 0.75 to 1 mg/kg. Methohexital is a short-acting barbiturate derivative with several characteristics that make it especially suitable for use in ECT: rapid onset of action, short duration, minimal anticonvulsant effects, rapid recovery, and low cost. The recommended dose of approximately 1 mg/kg of ideal body weight produces an appropriate level of anesthesia in 20 to 30 seconds [<a href="#rid54">54</a>]. Adverse effects of methohexital include pain on injection. (See  <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Methohexital'</a>.)</p><p></p><p class="bulletIndent1">Notably, an older barbiturate, thiopental, is no longer available in most nations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Propofol</strong> – <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">Propofol</a> has a rapid onset, inducing general anesthesia within 20 to 30 seconds after the bolus injection, with a duration of action of 8 to 10 minutes. Propofol is associated with a better recovery and hemodynamic effects compared with other induction agents [<a href="#rid55">55,56</a>].</p><p></p><p class="bulletIndent1">However, since <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> has significant anticonvulsant properties, a higher stimulus dose (voltage) is required to achieve adequate seizures [<a href="#rid57">57,58</a>], seizure duration may be reduced [<a href="#rid55">55,59,60</a>], and more severe cognitive side effects may occur after use of propofol for ECT [<a href="#rid61">61</a>]. Also, propofol has been associated with a shorter seizure duration and less improvement of depression than <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">methohexital</a> [<a href="#rid55">55,59,60</a>]. Furthermore, similar to methohexital, propofol is associated with pain on injection.</p><p></p><p class="bulletIndent1">Despite these disadvantages, <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> is used as an alternative to <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">methohexital</a> in some institutions, and may be preferentially selected for certain patients (eg, those with a history of prolonged seizures, postictal agitation, or severe postoperative nausea and vomiting [PONV]). (See  <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Propofol'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etomidate</strong> – <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">Etomidate</a> is a short-acting induction agent with a favorable hemodynamic profile compared with <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">methohexital</a> (ie, fewer cardiac side effects such as bradycardia and cardiac arrhythmias); thus, it is a good choice in patients who may develop cardiovascular instability [<a href="#rid62">62-64</a>]. Also, etomidate is associated with longer seizures compared with <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1">However, adrenal medullary suppression is a concern with use of <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">etomidate</a>. Although this side effect would theoretically render etomidate less useful for patients receiving multiple treatments, etomidate has not been specifically associated with clinically significant adrenocortical suppression during courses of ECT treatments [<a href="#rid66">66</a>]. Other adverse side effects include a higher incidence of PONV, myoclonus, and, similar to <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">methohexital</a> and <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a>, pain on injection. (See  <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Etomidate'</a> and  <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Disadvantages and adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ketamine</strong> – <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">Ketamine</a> is not often selected for use during an ECT procedure. However, in the last two decades, subanesthetic doses of ketamine (typically 0.5 mg/kg over 40 minutes) have been studied as a treatment for major depression or bipolar depression refractory to treatment, with successful diminishing of severity in selected patients within hours to one day after administration [<a href="#rid67">67-69</a>]. The intrinsic antidepressant effects<strong> </strong>of ketamine<strong> </strong>have led to investigation of its use as a sole anesthetic agent or as an adjunct in anesthesia for ECT. Although some studies have noted that ketamine in this setting increases seizure duration or results in significant cognitive improvement compared with other anesthetic agents [<a href="#rid70">70-73</a>], these findings are not consistent [<a href="#rid74">74-76</a>]. A 2020 meta-analysis noted that ketamine enhances seizure duration, thereby facilitating reduced dosing of the electrical current delivered to the brain [<a href="#rid77">77</a>]. However, ketamine did not enhance the antidepressant effect of ECT [<a href="#rid77">77</a>]. Similarly, a 2017 meta-analysis noted that ketamine was not associated with greater improvement in depressive symptoms or higher rates of clinical response or procognitive effects compared with barbiturate anesthetic induction agents [<a href="#rid75">75</a>]. Thus, use of ketamine is reasonable when ECT seizures are suboptimal. However, some newer studies suggest that subanesthetic doses of ketamine (0.3 mg/kg) could modulate the antidepressant efficacy of ECT by accelerating onset of its effects, thereby reducing the number of ECT sessions required to obtain response, remission, and suicidal ideation reduction [<a href="#rid78">78,79</a>]. (See  <a class="medical medical_review" href="/z/d/html/119992.html" rel="external">"Ketamine and esketamine for treating unipolar depression in adults: Administration, efficacy, and adverse effects"</a>.)</p><p></p><p class="bulletIndent1">Advantages of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> include its analgesic properties; thus, is often used as the sole agent for short painful procedures, particularly in patients with opioid tolerance or hyperalgesia. Also, ketamine is potentially useful for patients with severe asthma because of its bronchodilating properties. (See  <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Advantages and beneficial effects'</a>.)</p><p></p><p class="bulletIndent1">Potential adverse effects of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> include postprocedure confusion, restlessness, hallucinations, delusions, fear, derealization, and headache [<a href="#rid76">76,80-83</a>]. Also, the sympathomimetic effects of ketamine typically cause mild tachycardia and hypertension, which may increase myocardial O<sub>2</sub> demand. Thus, it is usually avoided in patients with ischemic heart disease. Furthermore, ketamine has been associated with QTc prolongation, an effect which may be particularly important in patients chronically receiving psychotropic medications that also prolong the QTc interval (see <a class="local">'Psychotropic medications: Anesthetic considerations'</a> above) [<a href="#rid84">84</a>]. In addition, ketamine increases salivation, which may be a problem in patients who do not have an endotracheal tube. For this reason, <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrrolate</a> is typically administered as a premedication when ketamine use is planned. (See  <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Disadvantages and adverse effects'</a> and <a class="local">'Anticholinergic administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combinations of </strong><strong>ketamine</strong><strong> and </strong><strong>propofol</strong> – To minimize the side effects of using either <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> or <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> alone, a combination of lower doses of ketamine and propofol (commonly known as "ketofol") has been employed by some clinicians for ECT procedures [<a href="#rid85">85,86</a>]. Inclusion of propofol mitigates some of the side effects of ketamine such as PONV, sympathomimetic effects, and psychotomimetic effects including recovery agitation, while inclusion of ketamine mitigates propofol-induced hypotension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combinations of </strong><strong>dexmedetomidine</strong> <strong>and </strong><strong>propofol</strong> – <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">Dexmedetomidine</a> is an alpha-2 agonist acting predominantly in the locus coeruleus that is commonly used for procedural and intensive care unit (ICU) sedation. A 2018 meta-analysis of the use of dexmedetomidine to supplement <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> induction for ECT procedures (six studies; 166 patients) noted that it did not interfere with seizure duration (measured with motor or electroencephalographic [EEG] parameters) and did not significantly prolong recovery time, but was associated with decreases in mean arterial pressure (MAP) and heart rate (HR) [<a href="#rid87">87</a>]. Other small trials have reported that preinduction dexmedetomidine use reduced the acute hyperdynamic responses to ECT (see <a class="local">'Management of hemodynamic responses'</a> below), with no effect on seizure duration but at the possible expense of a delayed recovery and discharge [<a href="#rid88">88-91</a>]. Additional small studies and case reports have also noted that dexmedetomidine reduces the incidence of post-ECT adverse effects such as headache, agitation, postictal delirium, or pain associated with propofol injection [<a href="#rid88">88,91-95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Remifentanil</strong> – <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">Remifentanil</a> is a potent mu-opioid receptor agonist with intense analgesic properties and a short duration of action due to rapid degradation via ester hydrolysis. Remifentanil has been used as a supplemental agent or as a sole anesthetic during ECT, and may result in longer seizure duration in patients refractory to seizure induction after standard <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">methohexital</a> or <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> anesthetic dosing [<a href="#rid96">96-102</a>]. In one small retrospective study, 24 patients who had become completely or relatively refractory to maximum settings on the ECT device after receiving bilateral ECT with a standard methohexital-based anesthetic, switching to remifentanil as the sole induction agent for subsequent ECT procedures was tried [<a href="#rid103">103</a>]. The stimulus dose was significantly lower with a remifentanil anesthetic induction in these patients, resulting in significantly longer motor and EEG seizure duration compared with methohexital. Remifentanil also attenuates the hypertensive response to ECT [<a href="#rid101">101</a>].</p><p></p><p class="bulletIndent1">However, <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> at usual doses does not have intrinsic properties to enhance ECT seizures [<a href="#rid104">104</a>]. Furthermore, repeated use for ECT may have short-term side effects such as dizziness, nausea, and headache, without demonstrable benefits in speed of response and remission rates [<a href="#rid105">105</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Volatile inhalation agents</strong> — Although general anesthesia for ECT is usually induced with IV agent(s), a volatile inhalation anesthetic may be used for induction in selected patients (eg, those with needle phobia, severe agitation preventing IV catheter placement, or poor tolerance of IV induction) [<a href="#rid106">106</a>]. <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">Sevoflurane</a> is the agent of choice for an inhalation induction because of its rapid onset and low incidence of airway irritation [<a href="#rid107">107</a>]. Although data regarding use of sevoflurane for ECT are limited, they suggest that the technique is safe, but may be associated with a shorter motor seizure duration compared with <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">methohexital</a>, although a longer seizure duration compared with <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> [<a href="#rid108">108-110</a>]. The undesirable effect of sevoflurane on seizure duration may be attenuated by discontinuing its administration after induction of anesthesia.</p><p></p><p class="bulletIndent1">Safety issues to consider when employing an inhalational induction in a location used for ECT are ensuring the ability to treat complications that may occur during an inhalation induction (eg, laryngospasm, arrhythmias, hypotension) if there is no IV catheter, as well as the availability of a gas scavenging system to avoid environmental contamination. (See  <a class="medical medical_review" href="/z/d/html/94135.html" rel="external">"Induction of general anesthesia: Overview", section on 'Inhalation anesthetic induction'</a> and  <a class="medical medical_review" href="/z/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Induction of general anesthesia'</a>.)</p><p></p><p class="headingAnchor" id="H1209150578"><span class="h2">Adjunct agents</span><span class="headingEndMark"> — </span>Addition of a short-acting opioid such as <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> or <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a> during induction of general anesthesia may reduce the necessary dose of <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> (or other induction agent), enhance analgesia during the procedure, and may also increase seizure duration.</p><p class="headingAnchor" id="H938104257"><span class="h2">Depth of anesthesia</span><span class="headingEndMark"> — </span>The patient must be rendered unconscious to prevent awareness before a neuromuscular blocking agent (NMBA) is administered (see <a class="local">'Neuromuscular blocking agents'</a> below). An appropriate level of anesthetic is confirmed by the anesthesiologist by noting loss of response to verbal commands and/or loss of eyelash reflex  (<a class="graphic graphic_table graphicRef107796" href="/z/d/graphic/107796.html" rel="external">table 3</a> and <a class="graphic graphic_figure graphicRef113985" href="/z/d/graphic/113985.html" rel="external">figure 1</a>). However, the eyelash reflex may not be lost when <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">methohexital</a> is used for induction even when the appropriate plane of anesthesia has been reached, and this may lead to administration of an unnecessarily high dose of methohexital, which may decrease seizure quality [<a href="#rid111">111</a>].</p><p>Processed EEG monitoring can be a useful aid to determine the optimal time for seizure induction in an unconscious patient  (<a class="graphic graphic_table graphicRef81084" href="/z/d/graphic/81084.html" rel="external">table 4</a>) [<a href="#rid112">112,113</a>]. Several studies have noted that seizure duration is best if the patient is maintained at a lighter level of anesthetic depth since intravenous induction agents have anticonvulsant properties [<a href="#rid114">114-118</a>]. A 2019 meta-analysis of bispectral index (BIS) monitoring during anesthesia for ECT noted that high preictal BIS values were associated with improved seizure duration and reduced incidence and magnitude of cognitive impairment after ECT [<a href="#rid119">119</a>]. However, limitations of BIS during ECT include the following (see  <a class="medical medical_review" href="/z/d/html/91216.html" rel="external">"Neuromonitoring in surgery and anesthesia", section on 'Intravenous agents'</a>) [<a href="#rid120">120</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The excitatory effects of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> may affect the validity of processed EEG-derived index values. Other combinations of anesthetic induction agents may also affect the validity of the BIS algorithm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of NMBAs interferes with BIS monitoring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pretreatment awake index values on the processed EEG may decline after the first ECT treatment, suggesting that the procedure itself may induce prolonged changes in EEG parameters [<a href="#rid121">121</a>]. Thus, index values may be unreliable after the first treatment. Some patients who have received a course of ECT may have BIS values in the anesthetized range even when awake.</p><p></p><p class="headingAnchor" id="H1517345564"><span class="h2">Neuromuscular blocking agents</span><span class="headingEndMark"> — </span>Neuromuscular blockade as a component of general anesthesia has made ECT more widely accepted and safer by minimizing the risk of physical trauma associated with uncontrolled tetanic muscle contractions. To check that the electrical stimulation has produced a tonic-clonic seizure, a standard blood pressure (BP) cuff or tourniquet is wrapped around an ankle and inflated at 20 percent above the systolic pressure to prevent paralysis in the foot, before the NMBA is administered to the anesthetized patient. This allows visual and tactile observation of the motor component of seizure activity in that foot.</p><p><a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">Succinylcholine</a> is the NMBA of choice for ECT procedures because of its rapid onset, short duration of action, and rapid recovery (see  <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Succinylcholine'</a>). Several studies suggest that a dose of 1 mg/kg will provide acceptable conditions for the procedure in most patients [<a href="#rid54">54,122,123</a>]. However, there is some variability in responsiveness to succinylcholine, so in patients who have a high risk of injury (eg, older adult patients with significant osteoporosis), the dose is typically increased by 40 to 50 percent to minimize the risk of excessive uncoordinated muscular contractions which may cause bone fractures [<a href="#rid124">124</a>]. There is also considerable variability in time to relaxation between patients. Thus, simply timing the stimulus application after administration of succinylcholine (one minute for younger patients and two minutes for older patients) is not adequate.</p><p>Electrical stimulation to produce the seizure should be applied only when maximal neuromuscular blockade has been achieved, as monitored with a peripheral nerve stimulator. While 50 percent twitch depression is found to provide optimal conditions for endotracheal intubation [<a href="#rid125">125,126</a>], near complete twitch suppression is necessary for optimal neuromuscular blockade during ECT [<a href="#rid122">122</a>]. Furthermore, even in the absence of twitch response to peripheral nerve stimulation, the ECT stimulus should only be applied once muscle fasciculations in the distal extremities have subsided completely, and the plantar reflex on the side without the ankle tourniquet has been abolished [<a href="#rid127">127</a>]. (See  <a class="medical medical_review" href="/z/d/html/114324.html" rel="external">"Monitoring neuromuscular blockade"</a>.)</p><p>Contraindications to <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a> include prolonged immobilization, muscular dystrophy, burns, malignant hyperthermia, and paralysis (eg, after a stroke). For these patients, a nondepolarizing NMBA should be used to achieve complete muscular relaxation for ECT. <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">Rocuronium</a> at a dose of 0.3 to 0.6 mg/kg offers a good alternative to succinylcholine [<a href="#rid122">122,128</a>]. If insufficient or excessive neuromuscular blockade is noticed during the convulsion in an individual patient, then the dose of rocuronium can be adjusted by 0.05 to 0.1 mg/kg to achieve a better result. Compared with succinylcholine, a disadvantage for use of rocuronium or any other nondepolarizing NMBA is a longer time from injection to the complete muscle relaxation. Another disadvantage is a longer duration of action compared with succinylcholine. (See  <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Nondepolarizing neuromuscular blocking agents'</a>.)</p><p>Complete return of neuromuscular function before allowing emergence from general anesthesia is ensured by using quantitative monitoring of the degree of residual blockade, ideally with monitoring of the hand muscles supplied by the ulnar nerve [<a href="#rid129">129</a>]. We employ <a class="drug drug_general" data-topicid="105866" href="/z/d/drug information/105866.html" rel="external">sugammadex</a> for reversal of <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">rocuronium</a> after ECT. Use of sugammadex reduces recovery times as measured using train of four (TOF) stimulation [<a href="#rid130">130</a>], times to spontaneous ventilation and eye opening [<a href="#rid131">131</a>], and postprocedure complaints such as myalgia and headache, compared to reversal of rocuronium with <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">neostigmine</a> [<a href="#rid131">131,132</a>]. (See  <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Reversal of neuromuscular block'</a> and  <a class="medical medical_review" href="/z/d/html/114324.html" rel="external">"Monitoring neuromuscular blockade"</a>.)</p><p class="headingAnchor" id="H3453806565"><span class="h2">Airway management</span><span class="headingEndMark"> — </span>Airway management is critically important during ECT, both to ensure patient safety during the general anesthetic and to facilitate hyperventilation and purposeful hypocapnia and hyperoxia as a strategy for augmentation of the ECT-induced seizures. (See <a class="local">'Management of oxygenation and ventilation'</a> below.)</p><p>Dental and oral soft tissue injuries can occur during seizures [<a href="#rid133">133</a>], and some ECT patients may have poor dentition [<a href="#rid134">134</a>]. In conscious patients, biting pressure is controlled by a feedback mechanism that prevents excessive strain, but such feedback is absent in anesthetized patients [<a href="#rid135">135</a>]. Also, forceful jaw clenching cannot be prevented by using a NMBA because the temporalis, masseter, and pterygoid muscles are directly stimulated by the electrodes. To prevent dental and alveolar bone damage as well as soft tissue injury, the American Psychiatric Association (APA) recommends using a bite guard made of flexible material with maximal cushioning in the molar area and inserted prior to electrical stimulation. Proper technique is to ensure that the tongue is pushed inferiorly and posteriorly in the mouth, and that the chin is held firmly against the bite block.</p><p>Most patients are efficiently ventilated using a face mask (eg, a bag-valve-mask device with an Ambu bag or the breathing circuit on an anesthesia machine). The Mapleson D circuit is not employed as it is less efficient for lowering the partial pressure of carbon dioxide (PaCO<sub>2</sub>) [<a href="#rid136">136</a>]. Endotracheal intubation is a reliable way to secure the airway and achieve hyperventilation but it is rarely used for a brief ECT procedure. Although the laryngeal mask airway (LMA) is minimally invasive, this technique is also not used routinely [<a href="#rid137">137</a>], but may be used in patients who are difficult to ventilate with a face mask [<a href="#rid138">138</a>], especially in patients with obesity [<a href="#rid139">139</a>].</p><p class="headingAnchor" id="H2763559125"><span class="h2">Management of oxygenation and ventilation</span><span class="headingEndMark"> — </span>After preoxygenation and induction of general anesthesia (see <a class="local">'Preoxygenation'</a> above and <a class="local">'Choice of induction agent'</a> above), we typically hyperventilate the patient using a bag-valve-mask device immediately prior to delivering the electrical stimulus. This induces cerebral hypocarbia with a target end-tidal carbon dioxide (EtCO<sub>2</sub>) of 30 mmHg. Hyperoxia and hypocapnia increase seizure intensity and duration, thereby optimizing ECT stimulus efficiency while minimizing postictal side effects [<a href="#rid102">102,140-144</a>]. Some studies suggest that hyperoxia and hypocapnia (with a moderately low PaCO<sub>2</sub>) act synergistically to improve seizure quality and reduce the electrical charge required to generate a therapeutic convulsion [<a href="#rid141">141,143</a>].</p><p>Strategies to prevent O<sub>2</sub> desaturation throughout the procedure include careful preoxygenation (see <a class="local">'Preoxygenation'</a> above), and administration of 100 percent supplemental oxygen as well as good airway control throughout the procedure, including emergence and recovery from general anesthesia [<a href="#rid145">145-147</a>]. It is thought that seizure duration is significantly impacted by the inspired oxygen concentration, although the mechanism underlying this phenomenon is not entirely clear [<a href="#rid145">145</a>]. There are no known clinically significant adverse effects of hyperoxia of short duration during ECT.</p><p>Induction of hypocapnia is particularly important in patients with a history of inadequate seizure length, and some studies found that the seizure threshold is also significantly lowered by hypocapnia [<a href="#rid142">142,148</a>]. Hypocapnia may lower the seizure threshold in patients affected by an increasing seizure threshold during consecutive ECT treatment, although evidence is not consistent [<a href="#rid149">149</a>]. Hypocapnia also reduces intracranial hypertension and thereby, the incidence of postictal headache and agitation [<a href="#rid150">150</a>]. Potential adverse effects of hypocapnia include coronary and cerebral vasoconstriction and an increased the risk of arrhythmias [<a href="#rid151">151</a>].</p><p>Hypercapnia secondary to poor ventilation is avoided as it has been associated with hypertension, tachycardia, somnolence, delayed recovery from anesthesia, and a higher prevalence of postprocedure agitation and headache [<a href="#rid152">152</a>]. Notably, use of the bag-valve-mask device may not allow accurate measurement of EtCO<sub>2</sub>. Although transcutaneous CO<sub>2</sub> pressure measurement may be an accurate noninvasive alternative, this technology is not widely available [<a href="#rid153">153</a>].</p><p class="headingAnchor" id="H3158631391"><span class="h2">Management of hemodynamic responses</span></p><p class="headingAnchor" id="H3888204652"><span class="h3">Parasympathetic responses</span><span class="headingEndMark"> — </span>Electrical stimulation to induce the seizure initially triggers bradycardia lasting for a brief period (10 to 15 seconds). This probably occurs because of a sudden increase in parasympathetic discharge to the sinoatrial node due to electrical stimulation of the motor nucleus of the vagus nerve and nucleus ambiguous within the medulla oblongata of the brain [<a href="#rid154">154</a>]. Asystole in the postictal period is very rare [<a href="#rid155">155,156</a>].</p><p>Asystole is often associated with chronically administered medications (see <a class="local">'Management of chronically administered medications'</a> above), administration of <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a>, or unusual ECT administration [<a href="#rid157">157,158</a>]. Asystole occurs more commonly after convulsive compared with nonconvulsive stimulations [<a href="#rid154">154</a>], and after electrode placement in the bitemporal or right unilateral positions compared with bifrontal electrode placement [<a href="#rid159">159</a>].</p><p>Bradycardia and/or asystole is self-limited in most patients undergoing ECT, and usually has no long-lasting effects, particularly in younger patients without significant heart disease [<a href="#rid160">160</a>]. In some cases, it is necessary to administer either <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> or <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrrolate</a> to treat severe or persistent bradycardia. (See  <a class="medical medical_review" href="/z/d/html/94357.html" rel="external">"Arrhythmias during anesthesia", section on 'Other bradyarrhythmias'</a>.)</p><p>Although administration of anticholinergic premedication (<a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrrolate</a> or <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a>) typically prevents bradycardia and asystole, prophylactic anticholinergic administration is not routine because of undesirable side effects. (See <a class="local">'Anticholinergic administration'</a> above.)</p><p class="headingAnchor" id="H3740495779"><span class="h3">Sympathetic responses</span><span class="headingEndMark"> — </span>The seizure itself triggers a sympathetic response which increases plasma levels of catecholamines resulting in tachycardia with an increase in HR of approximately 20 percent, hypertension with an increase in systolic BP of approximately 30 to 40 percent, and an increase in cardiac output of approximately 80 percent, lasting for five or more minutes [<a href="#rid161">161</a>]. Despite these significant hemodynamic changes, major adverse cardiac events (MACE) are rare after ECT [<a href="#rid162">162</a>]. (See <a class="local">'Cardiovascular complications'</a> below.)</p><p>Preparation for management of exaggerated or prolonged responses to sympathetic stimulation and close communication with the proceduralist are critically important. We typically administer <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">esmolol</a> 10 to 50 mg (which may be repeated every 5 to 15 minutes to achieve the desired effect) for prophylaxis or treatment of tachycardia and hypertension in response to seizure-induced sympathetic stimulation  (<a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">table 5</a>) [<a href="#rid163">163</a>]. Possible reduction in seizure duration at higher esmolol doses is unlikely to be clinically significant. Limited data suggest that landiolol (a short-acting IV beta blocker with similar kinetics but greater negative chronotropic effects than esmolol) may be a suitable alternative beta blocker in this setting. <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">Labetalol</a> is used by some clinicians, but has inconsistent cardiovascular effects during the first few minutes after the stimulation and a longer half-life than esmolol [<a href="#rid163">163</a>]. Other agents (eg, calcium channel blockers, direct vasodilators such as <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> or <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a>) may be used in selected patients to minimize the undesirable cardiovascular effects of the sympathetic response to seizure induction  (<a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/z/d/html/94532.html" rel="external">"Hemodynamic management during anesthesia in adults", section on 'Hypertension: Prevention and treatment'</a> and  <a class="medical medical_review" href="/z/d/html/94357.html" rel="external">"Arrhythmias during anesthesia", section on 'Pharmacologic treatment of tachycardia'</a>.)</p><p>Decisions regarding preemptive administration of beta blockers or other agents to minimize tachycardia and hypertension are based on preoperative assessment of the individual patient’s risk of cardiovascular complications, as well as the patient's responses during previous ECT treatments. (See  <a class="medical medical_review" href="/z/d/html/4817.html" rel="external">"Medical evaluation for electroconvulsive therapy", section on 'Cardiovascular effects'</a>.)</p><p class="headingAnchor" id="H2290388579"><span class="h1">MANAGEMENT OF ADVERSE EFFECTS DURING RECOVERY</span><span class="headingEndMark"> — </span>As with all procedures requiring general anesthesia, recovery in a post-anesthesia care unit (PACU) or recovery area with comparable equipment and personnel is necessary. (See  <a class="medical medical_review" href="/z/d/html/14946.html" rel="external">"Overview of post-anesthetic care for adult patients"</a>.)</p><p>Common adverse effects of ECT may be evident in the immediate postprocedure period, including headache, nausea, and postictal agitation. Major cardiovascular complications and neurologic complications are rare. Overall, medical morbidity and mortality rates after ECT treatment are low and comparable to other low-risk ambulatory procedures performed under general anesthesia [<a href="#rid164">164,165</a>]. (See  <a class="medical medical_review" href="/z/d/html/1709.html" rel="external">"Overview of electroconvulsive therapy (ECT) for adults", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H2586868990"><span class="h2">Headache</span><span class="headingEndMark"> — </span>Headache is the most common side effect of ECT, occurring in 26 to 85 percent of patients [<a href="#rid42">42</a>]. In most cases, the headache is transient and mild, peaks at two hours, and is responsive to over-the-counter analgesics such as <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> or <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> given after the ECT procedure [<a href="#rid166">166</a>].</p><p>Triptans are also effective for post-ECT headache [<a href="#rid167">167,168</a>]. In a study of 20 patients with post-ECT headache, <a class="drug drug_general" data-topicid="8517" href="/z/d/drug information/8517.html" rel="external">eletriptan</a> and <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> both reduced post-ECT headaches, but eletriptan was superior to acetaminophen at reducing the duration and intensity of headaches [<a href="#rid169">169</a>]. Cold therapy has also been found to be successful [<a href="#rid170">170</a>].</p><p class="headingAnchor" id="H2021890067"><span class="h2">Nausea</span><span class="headingEndMark"> — </span>Transient, postoperative nausea and vomiting (PONV) may occur in approximately 25 percent of patients after ECT [<a href="#rid6">6</a>]. Causes include anesthetic agents, hyperventilation with introduction of air into the stomach, the ECT treatment itself, and/or severe postprocedure headache. Standard antiemetics such as <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> are used when treatment is necessary. (See  <a class="medical medical_review" href="/z/d/html/16849.html" rel="external">"Postoperative nausea and vomiting", section on 'Antiemetics'</a>.)</p><p>Adverse effects of antiemetic agents such as <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> or <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> include rare development of serotonin syndrome if the patient is chronically taking a selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI) agent. Development of QTc interval prolongation is possible if a butyrophenone such as <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">droperidol</a> or <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> is selected to treat PONV in a patient who is chronically taking a tricyclic antidepressant agent (TCA). Administration of <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">scopolamine</a> to treat PONV may accentuate the anticholinergic side effects of TCAs, causing increased likelihood of postoperative delirium. (See <a class="local">'Psychotropic medications: Anesthetic considerations'</a> above.)</p><p><a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">Mirtazapine</a> has been successfully used to treat both post-ECT nausea and headache [<a href="#rid171">171</a>]. (See  <a class="medical medical_review" href="/z/d/html/16849.html" rel="external">"Postoperative nausea and vomiting", section on 'Antiemetics'</a>.)</p><p class="headingAnchor" id="H2634127280"><span class="h2">Adverse cognitive effects</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postictal agitation</strong> – Postictal agitation is a relatively frequent clinical problem reported in 10 percent of patients undergoing ECT [<a href="#rid172">172</a>]. It is an acute confusional state characterized by disorientation, restlessness, and poor response to verbal requests. It is usually associated with amnesia, and is mostly self-limiting [<a href="#rid173">173</a>]. Mild cases can be treated with supportive measures and behavioral interventions.</p><p></p><p class="bulletIndent1">In patients with a history of severe postictal agitation, intravenous (IV) benzodiazepines or <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> may be administered at the end of the seizure [<a href="#rid174">174,175</a>]. <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">Dexmedetomidine</a> may be useful in the treatment of refractory cases [<a href="#rid93">93,94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other cognitive effects</strong> – Longer-term cognitive side effects (eg, memory loss, long-term changes in cognition) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1709.html" rel="external">"Overview of electroconvulsive therapy (ECT) for adults", section on 'Adverse cognitive effects'</a>.)</p><p></p><p class="headingAnchor" id="H576017924"><span class="h2">Cardiovascular complications</span><span class="headingEndMark"> — </span>Major cardiovascular complications are relatively rare with ECT and almost always occur in older patients and those with underlying cardiovascular disease. Medical management of such patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4817.html" rel="external">"Medical evaluation for electroconvulsive therapy", section on 'Cardiovascular effects'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Major adverse cardiovascular events </strong>– Major adverse cardiac events (MACE) and death after ECT are rare, occurring in approximately 1 in 50 patients, and after approximately 1 in 200 to 500 ECT treatments [<a href="#rid162">162</a>]. In a 2019 meta-analysis of 82 studies that included 106,569 patients undergoing 786,995 ECT treatments, the most commonly reported MACE diagnoses were acute heart failure (2.4 per 1000 treatments; 95% CI 1.3-4.7), arrhythmia (4.7 per 1000 treatments; 95% CI 2.2-10.1), and acute pulmonary edema (1.5 per 1000 treatments; 95% CI 0.7-3.1) [<a href="#rid162">162</a>]. Notably, acute pulmonary edema after ECT may be associated with a hypertensive crisis [<a href="#rid176">176-178</a>], a cardiogenic cause [<a href="#rid161">161</a>], a neurogenic cause [<a href="#rid179">179</a>], or another etiology such as negative intrathoracic pressure associated with airway obstruction [<a href="#rid180">180,181</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myocardial ischemia</strong> – While the incidence of MACE after ECT is low, prospective studies have demonstrated that 5 to 10 percent of ECT treatment patients develop cardiac troponin elevation indicative of myocardial damage [<a href="#rid182">182,183</a>]. As noted above, prophylactic administration of a short-acting beta blocking agent is useful for prevention and treatment of tachycardia and hypertension due to sympathetic responses to ECT, particularly in patients at high risk of cardiovascular complications [<a href="#rid163">163,184</a>]. (See <a class="local">'Sympathetic responses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Takotsubo cardiomyopathy</strong> – Takotsubo cardiomyopathy is a transient and reversible stress-induced cardiomyopathy characterized by left ventricular hypokinesis and apical ballooning associated with ST segment elevations and increased cardiac enzymes. Seventeen case reports have described Takotsubo cardiomyopathy associated with ECT, primarily in older women (&gt;70 years) [<a href="#rid185">185</a>]. Limited evidence suggests that pretreatment with beta blockers would prevent recurrence during subsequent ECT procedures [<a href="#rid186">186</a>].</p><p></p><p class="headingAnchor" id="H549351796"><span class="h2">Neurologic complications</span><span class="headingEndMark"> — </span>Neurologic dysfunction following ECT is rare.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tardive seizures</strong> – Although rare, tardive seizures are a potentially fatal complication of ECT. Either nonconvulsive or focal seizures may occur spontaneously after the termination of convulsion from ECT, or after return to full consciousness [<a href="#rid187">187</a>]. Reported predisposing factors include electrolyte disturbance, benzodiazepine withdrawal, head trauma, pregnancy, neurologic disease, and antibiotics such as cefotiam, <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">piperacillin</a>, or <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> [<a href="#rid188">188-191</a>]. Rarely, tardive seizures may persist as convulsive or nonconvulsive status epilepticus. One review that included 13 case reports describing nonconvulsive status epilepticus after ECT noted that this diagnosis requires a high index of clinical suspicion and a confirmation by a multi-lead electroencephalogram (EEG) [<a href="#rid192">192</a>]. The first line of treatment includes IV benzodiazepines, followed by IV antiepileptic drugs if the seizure persists.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Focal neurologic deficits</strong> – Todd phenomenon is a rare transient postictal focal neurologic deficit (eg, aphasia, hemiparesis, visual loss) with complete spontaneous recovery after ECT [<a href="#rid187">187,193,194</a>]. Other causes of focal neurologic dysfunction should be ruled out (eg, cerebrovascular ischemia [<a href="#rid195">195</a>], ruptured aneurysm [<a href="#rid196">196,197</a>]).</p><p></p><p class="headingAnchor" id="H4245585239"><span class="h1">CONSIDERATIONS FOR ECT DURING THE COVID-19 PANDEMIC</span><span class="headingEndMark"> — </span>Although elective surgical and other interventional procedures have been postponed during the novel coronavirus disease 2019 (COVID-19) pandemic, urgent and emergency procedures are necessary. Some institutions have established interdisciplinary review processes to determine which patients require urgent interventions, including electroconvulsive therapy (ECT) [<a href="#rid198">198,199</a>]. The bag-mask ventilation technique that is typically used during ECT incurs high risk for aerosol generation and consequent infection of participating clinicians, particularly anesthesia providers managing the airway. Details regarding techniques for minimizing infection risks for clinicians and the environment during airway management and provision of anesthetic care are available in a separate topic. (See  <a class="medical medical_review" href="/z/d/html/140910.html" rel="external">"Overview of infection control during anesthetic care", section on 'Preventing infection transmission to providers'</a>.)</p><p>Specific strategies and precautions to minimize risk of infection during ECT procedures have been developed, although these may vary according to local resources, and data supporting the efficacy of such strategies individually or collectively are scant [<a href="#rid198">198,199</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prior to ECT treatment, each scheduled patient is screened for COVID-19 infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some institutions are using a designated operating room or a designated negative pressure room to perform ECT during the COVID-19 pandemic, rather than using an open space area that is close to other patient beds (such as the post-anesthesia care unit [PACU]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some institutions use a patient decolonization protocol before transport to the site where the ECT procedure will be performed with <a class="drug drug_general" data-topicid="113931" href="/z/d/drug information/113931.html" rel="external">hydrogen peroxide</a> oral rinsing, povidone-iodine nasal swabbing, and hand hygiene. A surgical mask is placed on the patient during transport.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All health care personnel involved in the patient's care wear personal protective equipment. Details are available in a separate topic (see  <a class="medical medical_review" href="/z/d/html/140910.html" rel="external">"Overview of infection control during anesthetic care", section on 'Preventing infection transmission to providers'</a>). Specific institution-dependent recommendations for COVID-19-negative patients undergoing an aerosol-generating procedure during the COVID-19 pandemic may vary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In some institutions, the patient is asked to self-insert a bite block into his or her mouth, then an anesthesia mask attached to a high efficiency particulate air (HEPA) filter is applied by an anesthesia team member and held in place with a head strap. In other institutions, a supraglottic airway (SGA) with an integrated bite block is inserted after induction to limit aerosolization during controlled ventilation, rather than using a bite block.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preoxygenation is accomplished with a low inflow of oxygen (O<sub>2</sub>), typically two to four L/minute.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After induction of anesthesia and electrical stimulation to induce the seizure, positive pressure ventilation is initiated if necessary. A two-person technique can be employed, with one anesthesia provider using two hands to ensure a good seal of the facemask and another provider delivering ventilation with small tidal volumes and low pressures to maintain adequate O<sub>2</sub> saturation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If hyperventilation is required for seizure induction or rescue ventilation, a bite-proof SGA is typically inserted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Upon return of adequate spontaneous ventilation and demonstrated ability to maintain a patent airway, the patient's surgical mask is reapplied. The anesthesia circuit, anesthesia mask, and bite block are removed and placed in a biohazard bag to be discarded.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During and after transport to a PACU, the surgical face mask is kept in place. If necessary to maintain adequate O<sub>2</sub> saturation, supplemental O<sub>2</sub> is administered via nasal cannula positioned <strong>under</strong> the surgical mask.</p><p></p><p class="headingAnchor" id="H2995751364"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116503.html" rel="external">"Society guideline links: Depressive disorders"</a>.)</p><p class="headingAnchor" id="H1456677164"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Electroconvulsive therapy (ECT) is a treatment for severe depression involving passage of a small brief current through the brain to induce a generalized seizure in a patient who is under general anesthesia. ECT may be performed in a variety of offsite or remote locations, including the post-anesthesia care unit (PACU), preoperative procedural areas, or a dedicated suite. Standard preparations for a general anesthetic are necessary. (See <a class="local">'Technical considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients presenting for ECT are often taking psychotropic medications (eg, selective serotonin reuptake inhibitors [SSRIs], tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs), anticonvulsants [eg, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>], <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, antipsychotic agents [eg, <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a>, <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">thioridazine</a>, <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">perphenazine</a>, <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a>], benzodiazepines). These drugs may have synergistic effects with ECT, and are usually continued during the periprocedural period. (See <a class="local">'Psychotropic medications: Anesthetic considerations'</a> above.)</p><p></p><p class="bulletIndent1">Exceptions include benzodiazepines which are typically tapered and discontinued, while <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> or anticonvulsants such as <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> and <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> are typically withheld on the evening before a planned ECT procedure.</p><p></p><p class="bulletIndent1">In patients taking MAOIs, indirect sympathomimetic agents such as <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">ephedrine</a> or metaraminol are avoided to prevent exaggerated vasopressor effects (ie, severe hypertension), but direct-acting catecholamines (<a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, norepinephrine) or vasopressors (eg, <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a>, <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a>) can be administered if slowly and carefully titrated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preanesthetic medications may be administered in selected patients to prevent or minimize common adverse effects associated with ECT (eg, headaches, nausea, bradyarrhythmias). Benzodiazepines are avoided due to anticonvulsant properties that would make seizure induction more difficult. (See <a class="local">'Preanesthetic medications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The selected anesthetic induction agent(s) should not interfere with inducing an effective grand mal seizure. <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">Methohexital</a> is the agent of choice, administered intravenously at a dose of 0.75 to 1 mg/kg. Advantages include rapid onset of action, short duration, minimal anticonvulsant effects, rapid recovery, and low cost. Other anesthetic induction agents include <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> and <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">etomidate</a>. (See <a class="local">'Choice of induction agent'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient must be rendered unconscious to prevent awareness before the administration of neuromuscular blocking agent (NMBA). An appropriate level of anesthetic is confirmed by the anesthesiologist by noting loss of response to verbal commands and/or loss of eyelash reflex. (See <a class="local">'Depth of anesthesia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">Succinylcholine</a> 1 mg/kg is the NMBA of choice because of its rapid onset, short duration of action, and rapid recovery. A higher dose may be used in selected patients. To check that the electrical stimulation has produced a tonic-clonic seizure, a standard blood pressure cuff or tourniquet is wrapped around an ankle and inflated at 20 percent above the systolic pressure to prevent paralysis in the foot before the NMBA is administered. This allows visual and tactile observation of the motor component of seizure activity in that foot. Electrical stimulation to produce the seizure should be applied only when maximal neuromuscular blockade has been achieved, as monitored with a peripheral nerve stimulator. (See <a class="local">'Neuromuscular blocking agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To prevent dental and alveolar bone damage as well as soft tissue injury, a bite guard made of flexible material with maximal cushioning in the molar area is used. Most patients are efficiently ventilated using a face mask (eg, a bag-valve-mask device). (See <a class="local">'Airway management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preoxygenation via nasal cannula or face mask during spontaneous ventilation is accomplished before induction of general anesthesia to maintain oxygen (O<sub>2</sub>) saturation at or near 100 percent. After induction of general anesthesia, the patient is typically hyperventilated immediately prior to delivering the ECT stimulus. This induces cerebral hypocarbia with a target end-tidal carbon dioxide (EtCO<sub>2</sub>) of approximately 30 mmHg. Hyperoxia and hypocapnia increase seizure intensity and duration, thereby optimizing ECT stimulus efficiency while minimizing postictal side effects. (See <a class="local">'Preoxygenation'</a> above and <a class="local">'Management of oxygenation and ventilation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrical stimulation to induce the seizure initially triggers bradycardia and/or asystole that is self-limited in most patients, lasting for a brief period (10 to 15 seconds) [<a href="#rid200">200</a>]. If severe or persistent, either <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> or <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrrolate</a> is administered. (See <a class="local">'Parasympathetic responses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The seizure itself triggers a sympathetic response which increases plasma levels of catecholamines resulting in tachycardia with an increase in heart rate of approximately 20 percent, hypertension with an increase in systolic blood pressure of approximately 30 to 40 percent, and an increase in cardiac output of approximately 80 percent, lasting for five or more minutes. A short-acting beta blocker (eg, <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">esmolol</a>, landiolol, <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">labetalol</a>) or other agent (eg, calcium channel blockers, direct vasodilators such as <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> or <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a>) is used for prophylaxis or treatment of these effects if necessary  (<a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">table 5</a>). (See <a class="local">'Sympathetic responses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As with all procedures requiring general anesthesia, recovery in a PACU or recovery area with comparable equipment and personnel is necessary. Common adverse effects may be evident in the immediate postprocedure period, including headache, nausea, and postictal agitation. Major cardiovascular or neurologic complications are rare. (See <a class="local">'Management of adverse effects during recovery'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">American Society of Anesthesiologists. Standards for Basic Anesthetic Monitoring. www.asahq.org/Search.aspx?q=standards+basic+anesthetic+monitoring (Accessed on March 29, 2016).</li><li class="breakAll">https://www.asahq.org/standards-and-guidelines (Accessed on May 21, 2019).</li><li><a class="nounderline abstract_t">Radman T, Lisanby SH. New directions in the rational design of electrical and magnetic seizure therapies: individualized Low Amplitude Seizure Therapy (iLAST) and Magnetic Seizure Therapy (MST). Int Rev Psychiatry 2017; 29:63.</a></li><li><a class="nounderline abstract_t">Engel A, Kayser S. An overview on clinical aspects in magnetic seizure therapy. J Neural Transm (Vienna) 2016; 123:1139.</a></li><li class="breakAll">American Psychiatric Association, Weiner RD, Coffey CE. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, 2nd ed., American Psychiatric Association, 2001.</li><li><a class="nounderline abstract_t">Bryson EO, Aloysi AS, Farber KG, Kellner CH. Individualized Anesthetic Management for Patients Undergoing Electroconvulsive Therapy: A Review of Current Practice. Anesth Analg 2017; 124:1943.</a></li><li><a class="nounderline abstract_t">Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol 2009; 114:703.</a></li><li><a class="nounderline abstract_t">Calaway K, Coshal S, Jones K, et al. A Systematic Review of the Safety of Electroconvulsive Therapy Use During the First Trimester of Pregnancy. J ECT 2016; 32:230.</a></li><li><a class="nounderline abstract_t">Srejic U, Larson P, Bickler PE. Little Black Boxes: Noncardiac Implantable Electronic Medical Devices and Their Anesthetic and Surgical Implications. Anesth Analg 2017; 125:124.</a></li><li><a class="nounderline abstract_t">Gahr M, Connemann BJ, Freudenmann RW, Schönfeldt-Lecuona C. Safety of electroconvulsive therapy in the presence of cranial metallic objects. J ECT 2014; 30:62.</a></li><li><a class="nounderline abstract_t">Peroski MS, Chu MM, Doddi SR, Regenold WT. The Safety of Electroconvulsive Therapy in Patients With Implanted Deep Brain Stimulators: A Review of the Literature and Case Report. J ECT 2019; 35:84.</a></li><li><a class="nounderline abstract_t">Müller TC, Rocha JB, Morsch VM, et al. Antidepressants inhibit human acetylcholinesterase and butyrylcholinesterase activity. Biochim Biophys Acta 2002; 1587:92.</a></li><li><a class="nounderline abstract_t">Bahar MA, Hak E, Bos JHJ, et al. The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly. Pharmacoepidemiol Drug Saf 2017; 26:752.</a></li><li><a class="nounderline abstract_t">Ereshefsky L, Riesenman C, Lam YW. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet 1995; 29 Suppl 1:10.</a></li><li><a class="nounderline abstract_t">Gollapudy S, Kumar V, Dhamee MS. A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. J Clin Anesth 2012; 24:251.</a></li><li><a class="nounderline abstract_t">Turkel SB, Nadala JG, Wincor MZ. Possible serotonin syndrome in association with 5-HT(3) antagonist agents. Psychosomatics 2001; 42:258.</a></li><li><a class="nounderline abstract_t">Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352:1112.</a></li><li><a class="nounderline abstract_t">Ailawadhi S, Sung KW, Carlson LA, Baer MR. Serotonin syndrome caused by interaction between citalopram and fentanyl. J Clin Pharm Ther 2007; 32:199.</a></li><li><a class="nounderline abstract_t">Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 2005; 95:434.</a></li><li><a class="nounderline abstract_t">Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol 1999; 13:100.</a></li><li class="breakAll">Depaulo JR, Barker LR. Affective disorders. In: Principles of Ambulatory Medicine, Barker LR, Burton JR, Zieve PD (Eds), Williams and Wilkins, Baltimore 1995. p.166.</li><li class="breakAll">American Psychiatric Association. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging: A Task Force Report of the American Psychiatric Association, 2nd ed, American Psychiatric Association, Washington 2001.</li><li><a class="nounderline abstract_t">Dolenc TJ, Rasmussen KG. The safety of electroconvulsive therapy and lithium in combination: a case series and review of the literature. J ECT 2005; 21:165.</a></li><li><a class="nounderline abstract_t">Hill GE, Wong KC, Hodges MR. Potentiation of succinylcholine neuromuscular blockade by lithium carbonate. Anesthesiology 1976; 44:439.</a></li><li><a class="nounderline abstract_t">Hill GE, Wong KC, Hodges MR. Lithium carbonate and neuromuscular blocking agents. Anesthesiology 1977; 46:122.</a></li><li><a class="nounderline abstract_t">Sienaert P, Peuskens J. Anticonvulsants during electroconvulsive therapy: review and recommendations. J ECT 2007; 23:120.</a></li><li><a class="nounderline abstract_t">Nitturkar AR, Sinha P, Bagewadi VI, Thirthalli J. Effect of age and anticonvulsants on seizure threshold during bilateral electroconvulsive therapy with brief-pulse stimulus: A chart-based analysis. Indian J Psychiatry 2016; 58:190.</a></li><li><a class="nounderline abstract_t">Rakesh G, Thirthalli J, Kumar CN, et al. Concomitant Anticonvulsants With Bitemporal Electroconvulsive Therapy: A Randomized Controlled Trial With Clinical and Neurobiological Application. J ECT 2017; 33:16.</a></li><li><a class="nounderline abstract_t">Hızlı Sayar G, Eryılmaz G, Semieoğlu S, et al. Influence of valproate on the required dose of propofol for anesthesia during electroconvulsive therapy of bipolar affective disorder patients. Neuropsychiatr Dis Treat 2014; 10:433.</a></li><li><a class="nounderline abstract_t">Naguib M, Koorn R. Interactions between psychotropics, anaesthetics and electroconvulsive therapy: implications for drug choice and patient management. CNS Drugs 2002; 16:229.</a></li><li><a class="nounderline abstract_t">Bezinover D, Postula M, Donahue K, et al. Perioperative exacerbation of valproic acid-associated hyperammonemia: a clinical and genetic analysis. Anesth Analg 2011; 113:858.</a></li><li><a class="nounderline abstract_t">Nothdurfter C, Eser D, Schüle C, et al. The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World J Biol Psychiatry 2006; 7:162.</a></li><li><a class="nounderline abstract_t">Desarkar P, Blumberger D, Daskalakis ZJ. Case Report: Successful Use of the Combination of Electroconvulsive Therapy and Clozapine in Treating Treatment-Resistant Schizophrenia and Catatonia in an Adult with Intellectual Disability. J Autism Dev Disord 2018; 48:3637.</a></li><li><a class="nounderline abstract_t">Petrides G, Malur C, Braga RJ, et al. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry 2015; 172:52.</a></li><li><a class="nounderline abstract_t">Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos 1999; 27:1078.</a></li><li><a class="nounderline abstract_t">Velamoor VR. Neuroleptic malignant syndrome. Recognition, prevention and management. Drug Saf 1998; 19:73.</a></li><li><a class="nounderline abstract_t">Velamoor R. Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management. Asian J Psychiatr 2017; 29:106.</a></li><li><a class="nounderline abstract_t">Coulter DM, Bate A, Meyboom RH, et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001; 322:1207.</a></li><li><a class="nounderline abstract_t">Zorumski CF, Isenberg KE. Insights into the structure and function of GABA-benzodiazepine receptors: ion channels and psychiatry. Am J Psychiatry 1991; 148:162.</a></li><li><a class="nounderline abstract_t">Pettinati HM, Stephens SM, Willis KM, Robin SE. Evidence for less improvement in depression in patients taking benzodiazepines during unilateral ECT. Am J Psychiatry 1990; 147:1029.</a></li><li><a class="nounderline abstract_t">Delamarre L, Galvao F, Gohier B, et al. How Much Do Benzodiazepines Matter for Electroconvulsive Therapy in Patients With Major Depression? J ECT 2019; 35:184.</a></li><li><a class="nounderline abstract_t">Andrade C, Arumugham SS, Thirthalli J. Adverse Effects of Electroconvulsive Therapy. Psychiatr Clin North Am 2016; 39:513.</a></li><li><a class="nounderline abstract_t">Datto CJ. Side effects of electroconvulsive therapy. Depress Anxiety 2000; 12:130.</a></li><li><a class="nounderline abstract_t">Weiner SJ, Ward TN, Ravaris CL. Headache and electroconvulsive therapy. Headache 1994; 34:155.</a></li><li><a class="nounderline abstract_t">Mulder LAC, Grootens KP. The Incidence of Post-Electroconvulsive Therapy Headache: A Systematic Review. J ECT 2020; 36:e22.</a></li><li><a class="nounderline abstract_t">Isuru A, Rodrigo A, Wijesinghe C, et al. A randomized, double-blind, placebo-controlled trial on the role of preemptive analgesia with acetaminophen [paracetamol] in reducing headache following electroconvulsive therapy [ECT]. BMC Psychiatry 2017; 17:275.</a></li><li><a class="nounderline abstract_t">Leung M, Hollander Y, Brown GR. Pretreatment with ibuprofen to prevent electroconvulsive therapy-induced headache. J Clin Psychiatry 2003; 64:551.</a></li><li><a class="nounderline abstract_t">Gillis JC, Brogden RN. Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 1997; 53:139.</a></li><li><a class="nounderline abstract_t">Suzuki Y, Miyajima M, Ohta K, et al. Is prolongation of corrected QT interval associated with seizures induced by electroconvulsive therapy reduced by atropine sulfate? Pacing Clin Electrophysiol 2017; 40:1246.</a></li><li><a class="nounderline abstract_t">Anastasian ZH, Khan N, Heyer EJ, et al. Effect of atropine dose on heart rate during electroconvulsive therapy. J ECT 2014; 30:298.</a></li><li><a class="nounderline abstract_t">Christensen STJ, Staalsø JM, Jørgensen A, et al. Electro convulsive therapy: Modification of its effect on the autonomic nervous system using anti-cholinergic drugs. Psychiatry Res 2019; 271:239.</a></li><li><a class="nounderline abstract_t">Surve R, Bansal S, Sriganesh K, et al. Incidence and risk factors for oxygen desaturation during recovery from modified electroconvulsive therapy: A prospective observational study. J Anaesthesiol Clin Pharmacol 2015; 31:99.</a></li><li><a class="nounderline abstract_t">Kronsell A, Nordenskjöld A, Bell M, et al. The effect of anaesthetic dose on response and remission in electroconvulsive therapy for major depressive disorder: nationwide register-based cohort study. BJPsych Open 2021; 7:e71.</a></li><li><a class="nounderline abstract_t">Bryson EO, Aloysi AS, Popeo DM, et al. Methohexital and succinylcholine dosing for electroconvulsive therapy (ECT): actual versus ideal. J ECT 2012; 28:e29.</a></li><li><a class="nounderline abstract_t">Fredman B, d'Etienne J, Smith I, et al. Anesthesia for electroconvulsive therapy: effects of propofol and methohexital on seizure activity and recovery. Anesth Analg 1994; 79:75.</a></li><li><a class="nounderline abstract_t">Geretsegger C, Nickel M, Judendorfer B, et al. Propofol and methohexital as anesthetic agents for electroconvulsive therapy: a randomized, double-blind comparison of electroconvulsive therapy seizure quality, therapeutic efficacy, and cognitive performance. J ECT 2007; 23:239.</a></li><li><a class="nounderline abstract_t">Modica PA, Tempelhoff R, White PF. Pro- and anticonvulsant effects of anesthetics (Part II). Anesth Analg 1990; 70:433.</a></li><li><a class="nounderline abstract_t">Vaidya PV, Anderson EL, Bobb A, et al. A within-subject comparison of propofol and methohexital anesthesia for electroconvulsive therapy. J ECT 2012; 28:14.</a></li><li><a class="nounderline abstract_t">Fond G, Bennabi D, Haffen E, et al. A Bayesian framework systematic review and meta-analysis of anesthetic agents effectiveness/tolerability profile in electroconvulsive therapy for major depression. Sci Rep 2016; 6:19847.</a></li><li><a class="nounderline abstract_t">Lihua P, Su M, Ke W, Ziemann-Gimmel P. Different regimens of intravenous sedatives or hypnotics for electroconvulsive therapy (ECT) in adult patients with depression. Cochrane Database Syst Rev 2014; :CD009763.</a></li><li><a class="nounderline abstract_t">Bauer J, Hageman I, Dam H, et al. Comparison of propofol and thiopental as anesthetic agents for electroconvulsive therapy: a randomized, blinded comparison of seizure duration, stimulus charge, clinical effect, and cognitive side effects. J ECT 2009; 25:85.</a></li><li><a class="nounderline abstract_t">Janouschek H, Nickl-Jockschat T, Haeck M, et al. Comparison of methohexital and etomidate as anesthetic agents for electroconvulsive therapy in affective and psychotic disorders. J Psychiatr Res 2013; 47:686.</a></li><li><a class="nounderline abstract_t">Bergen JM, Smith DC. A review of etomidate for rapid sequence intubation in the emergency department. J Emerg Med 1997; 15:221.</a></li><li><a class="nounderline abstract_t">Zed PJ, Abu-Laban RB, Harrison DW. Intubating conditions and hemodynamic effects of etomidate for rapid sequence intubation in the emergency department: an observational cohort study. Acad Emerg Med 2006; 13:378.</a></li><li><a class="nounderline abstract_t">Singh PM, Arora S, Borle A, et al. Evaluation of Etomidate for Seizure Duration in Electroconvulsive Therapy: A Systematic Review and Meta-analysis. J ECT 2015; 31:213.</a></li><li><a class="nounderline abstract_t">Lebowitz P. Etomidate is still a valid anesthetic for electroconvulsive therapy. J ECT 2014; 30:261.</a></li><li><a class="nounderline abstract_t">Andrade C. Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action. J Clin Psychiatry 2017; 78:e415.</a></li><li><a class="nounderline abstract_t">Zarate C, Duman RS, Liu G, et al. New paradigms for treatment-resistant depression. Ann N Y Acad Sci 2013; 1292:21.</a></li><li><a class="nounderline abstract_t">Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 2013; 73:1133.</a></li><li><a class="nounderline abstract_t">Krystal AD, Weiner RD, Dean MD, et al. Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT. J Neuropsychiatry Clin Neurosci 2003; 15:27.</a></li><li><a class="nounderline abstract_t">Rasmussen KG, Kung S, Lapid MI, et al. A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy. Psychiatry Res 2014; 215:362.</a></li><li><a class="nounderline abstract_t">Yoosefi A, Sepehri AS, Kargar M, et al. Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study. J ECT 2014; 30:15.</a></li><li><a class="nounderline abstract_t">Gamble JJ, Bi H, Bowen R, et al. Ketamine-based anesthesia improves electroconvulsive therapy outcomes: a randomized-controlled study. Can J Anaesth 2018; 65:636.</a></li><li><a class="nounderline abstract_t">Loo CK, Katalinic N, Garfield JB, et al. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. J Affect Disord 2012; 142:233.</a></li><li><a class="nounderline abstract_t">McGirr A, Berlim MT, Bond DJ, et al. Adjunctive ketamine in electroconvulsive therapy: updated systematic review and meta-analysis. Br J Psychiatry 2017; 210:403.</a></li><li><a class="nounderline abstract_t">Cobb K, Nanda M. Ketamine and electroconvulsive therapy: so happy together? Curr Opin Anaesthesiol 2018; 31:459.</a></li><li><a class="nounderline abstract_t">Ainsworth NJ, Sepehry AA, Vila-Rodriguez F. Effects of Ketamine Anesthesia on Efficacy, Tolerability, Seizure Response, and Neurocognitive Outcomes in Electroconvulsive Therapy: A Comprehensive Meta-analysis of Double-Blind Randomized Controlled Trials. J ECT 2020; 36:94.</a></li><li><a class="nounderline abstract_t">Chen Q, Dong J, Luo J, et al. Effects of Low-Dose Ketamine on the Antidepressant Efficacy and Suicidal Ideations in Patients Undergoing Electroconvulsive Therapy. J ECT 2020; 36:25.</a></li><li><a class="nounderline abstract_t">Zheng W, Li XH, Zhu XM, et al. Adjunctive ketamine and electroconvulsive therapy for major depressive disorder: A meta-analysis of randomized controlled trials. J Affect Disord 2019; 250:123.</a></li><li><a class="nounderline abstract_t">Järventausta K, Chrapek W, Kampman O, et al. Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study. J ECT 2013; 29:158.</a></li><li><a class="nounderline abstract_t">Salehi B, Mohammadbeigi A, Kamali AR, et al. Impact comparison of ketamine and sodium thiopental on anesthesia during electroconvulsive therapy in major depression patients with drug-resistant; a double-blind randomized clinical trial. Ann Card Anaesth 2015; 18:486.</a></li><li><a class="nounderline abstract_t">Rybakowski JK, Bodnar A, Krzywotulski M, et al. Ketamine Anesthesia, Efficacy of Electroconvulsive Therapy, and Cognitive Functions in Treatment-Resistant Depression. J ECT 2016; 32:164.</a></li><li><a class="nounderline abstract_t">Abdallah CG, Fasula M, Kelmendi B, et al. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. J ECT 2012; 28:157.</a></li><li><a class="nounderline abstract_t">Erdil F, Begeç Z, Kayhan GE, et al. Effects of sevoflurane or ketamine on the QTc interval during electroconvulsive therapy. J Anesth 2015; 29:180.</a></li><li><a class="nounderline abstract_t">Yalcin S, Aydoğan H, Selek S, et al. Ketofol in electroconvulsive therapy anesthesia: two stones for one bird. J Anesth 2012; 26:562.</a></li><li><a class="nounderline abstract_t">Wang X, Chen Y, Zhou X, et al. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. J ECT 2012; 28:128.</a></li><li><a class="nounderline abstract_t">Li X, Tan F, Cheng N, et al. Dexmedetomidine Combined With Intravenous Anesthetics in Electroconvulsive Therapy: A Meta-analysis and Systematic Review. J ECT 2017; 33:152.</a></li><li><a class="nounderline abstract_t">Li X, Chen CJ, Tan F, et al. Effect of dexmedetomidine for attenuation of propofol injection pain in electroconvulsive therapy: a randomized controlled study. J Anesth 2018; 32:70.</a></li><li><a class="nounderline abstract_t">Sannakki D, Dalvi NP, Sannakki S, et al. Effectiveness of dexmedetomidine as premedication prior to electroconvulsive therapy, a Randomized controlled cross over study. Indian J Psychiatry 2017; 59:370.</a></li><li><a class="nounderline abstract_t">Parikh DA, Garg SN, Dalvi NP, et al. Outcome of four pretreatment regimes on hemodynamics during electroconvulsive therapy: A double-blind randomized controlled crossover trial. Ann Card Anaesth 2017; 20:93.</a></li><li><a class="nounderline abstract_t">Li X, Tan F, Jian CJ, et al. Effects of small-dose dexmedetomidine on hyperdynamic responses to electroconvulsive therapy. J Chin Med Assoc 2017; 80:476.</a></li><li><a class="nounderline abstract_t">Aksay SS, Bumb JM, Remennik D, et al. Dexmedetomidine for the management of postictal agitation after electroconvulsive therapy with S-ketamine anesthesia. Neuropsychiatr Dis Treat 2017; 13:1389.</a></li><li><a class="nounderline abstract_t">Bryson EO, Briggs MC, Pasculli RM, Kellner CH. Treatment-resistant postictal agitation after electroconvulsive therapy (ECT) controlled with dexmedetomidine. J ECT 2013; 29:e18.</a></li><li><a class="nounderline abstract_t">O'Brien EM, Rosenquist PB, Kimball JN, et al. Dexmedetomidine and the successful management of electroconvulsive therapy postictal agitation: a case report. J ECT 2010; 26:131.</a></li><li><a class="nounderline abstract_t">Qiu Z, Zhou S, Zhang M, et al. Preventive effect of dexmedetomidine on postictal delirium after electroconvulsive therapy: A randomised controlled study. Eur J Anaesthesiol 2020; 37:5.</a></li><li><a class="nounderline abstract_t">Chen ST. Remifentanil: a review of its use in electroconvulsive therapy. J ECT 2011; 27:323.</a></li><li><a class="nounderline abstract_t">Porter R, Booth D, Gray H, Frampton C. Effects of the addition of remifentanil to propofol anesthesia on seizure length and postictal suppression index in electroconvulsive therapy. J ECT 2008; 24:203.</a></li><li><a class="nounderline abstract_t">Akcaboy ZN, Akcaboy EY, Yigitbasł B, et al. Effects of remifentanil and alfentanil on seizure duration, stimulus amplitudes and recovery parameters during ECT. Acta Anaesthesiol Scand 2005; 49:1068.</a></li><li><a class="nounderline abstract_t">Andersen FA, Arsland D, Holst-Larsen H. Effects of combined methohexitone-remifentanil anaesthesia in electroconvulsive therapy. Acta Anaesthesiol Scand 2001; 45:830.</a></li><li><a class="nounderline abstract_t">MacPherson R, Marroquin-Harris M, Gálvez V, et al. The effect of adjuvant remifentanil with propofol or thiopentone on seizure quality during electroconvulsive therapy. Anaesth Intensive Care 2016; 44:278.</a></li><li><a class="nounderline abstract_t">Takekita Y, Suwa T, Sunada N, et al. Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials. Eur Arch Psychiatry Clin Neurosci 2016; 266:703.</a></li><li><a class="nounderline abstract_t">Nishikawa K, Yamakage M. Effects of the concurrent use of a reduced dose of propofol with divided supplemental remifentanil and moderate hyperventilation on duration and morphology of electroconvulsive therapy-induced electroencephalographic seizure activity: A randomized controlled trial. J Clin Anesth 2017; 37:63.</a></li><li><a class="nounderline abstract_t">Sullivan PM, Sinz EH, Cain J, et al. A retrospective comparison of remifentanil versus methohexital for anesthesia in electroconvulsive therapy. J ECT 2004; 20:219.</a></li><li><a class="nounderline abstract_t">Gálvez V, Tor PC, Bassa A, et al. Does remifentanil improve ECT seizure quality? Eur Arch Psychiatry Clin Neurosci 2016; 266:719.</a></li><li><a class="nounderline abstract_t">Kessler U, Bjorke-Bertheussen J, Søreide E, et al. Remifentanil as an adjunct to anaesthesia for electroconvulsive therapy fails to confer long-term benefits. Br J Anaesth 2018; 121:1282.</a></li><li><a class="nounderline abstract_t">Rasmussen KG, Spackman TN, Hooten WM. The clinical utility of inhalational anesthesia with sevoflurane in electroconvulsive therapy. J ECT 2005; 21:239.</a></li><li><a class="nounderline abstract_t">Patel SS, Goa KL. Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia. Drugs 1996; 51:658.</a></li><li><a class="nounderline abstract_t">Calarge CA, Crowe RR, Gergis SD, et al. The comparative effects of sevoflurane and methohexital for electroconvulsive therapy. J ECT 2003; 19:221.</a></li><li><a class="nounderline abstract_t">Toprak HI, Gedik E, Begeç Z, et al. Sevoflurane as an alternative anaesthetic for electroconvulsive therapy. J ECT 2005; 21:108.</a></li><li><a class="nounderline abstract_t">Andrade C. Anesthesia for Electroconvulsive Therapy: A Niche Role for Sevoflurane. J Clin Psychiatry 2021; 82.</a></li><li><a class="nounderline abstract_t">Strickland TL, Drummond GB. Comparison of pattern of breathing with other measures of induction of anaesthesia, using propofol, methohexital, and sevoflurane. Br J Anaesth 2001; 86:639.</a></li><li><a class="nounderline abstract_t">Sartorius A, Muñoz-Canales EM, Krumm B, et al. ECT anesthesia: the lighter the better? Pharmacopsychiatry 2006; 39:201.</a></li><li><a class="nounderline abstract_t">Nishihara F, Saito S. Pre-ictal bispectral index has a positive correlation with seizure duration during electroconvulsive therapy. Anesth Analg 2002; 94:1249.</a></li><li><a class="nounderline abstract_t">Ochiai R, Yamada T, Kiyama S, et al. Bispectral index as an indicator of seizure inducibility in electroconvulsive therapy under thiopental anesthesia. Anesth Analg 2004; 98:1030.</a></li><li><a class="nounderline abstract_t">Nishihara F, Saito S. Adjustment of anaesthesia depth using bispectral index prolongs seizure duration in electroconvulsive therapy. Anaesth Intensive Care 2004; 32:661.</a></li><li><a class="nounderline abstract_t">Gombar S, Aggarwal D, Khanna AK, et al. The bispectral electroencephalogram during modified electroconvulsive therapy under propofol anesthesia: relation with seizure duration and awakening. J ECT 2011; 27:114.</a></li><li><a class="nounderline abstract_t">Kranaster L, Hoyer C, Janke C, Sartorius A. Bispectral index monitoring and seizure quality optimization in electroconvulsive therapy. Pharmacopsychiatry 2013; 46:147.</a></li><li><a class="nounderline abstract_t">Kayser S, Bewernick BH, Soehle M, et al. Degree of Postictal Suppression Depends on Seizure Induction Time in Magnetic Seizure Therapy and Electroconvulsive Therapy. J ECT 2017; 33:167.</a></li><li><a class="nounderline abstract_t">Guerrier G, Gianni MA. The effectiveness of BIS monitoring during electro-convulsive therapy: A systematic review and meta-analysis. J Clin Anesth 2019; 58:100.</a></li><li><a class="nounderline abstract_t">Hans P, Dewandre PY, Brichant JF, Bonhomme V. Comparative effects of ketamine on Bispectral Index and spectral entropy of the electroencephalogram under sevoflurane anaesthesia. Br J Anaesth 2005; 94:336.</a></li><li><a class="nounderline abstract_t">Thimmaiah R, Thirthalli J, Ramesh VJ, et al. Effect of a course of electroconvulsive therapy on interictal bispectral index values: a prospective study. J ECT 2012; 28:20.</a></li><li><a class="nounderline abstract_t">Mirzakhani H, Guchelaar HJ, Welch CA, et al. Minimum Effective Doses of Succinylcholine and Rocuronium During Electroconvulsive Therapy: A Prospective, Randomized, Crossover Trial. Anesth Analg 2016; 123:587.</a></li><li><a class="nounderline abstract_t">Bryson EO, Kellner CH, Li EH, et al. Extreme variability in succinylcholine dose for muscle relaxation in electroconvulsive therapy. Australas Psychiatry 2018; 26:391.</a></li><li><a class="nounderline abstract_t">Briggs MC, Popeo DM, Pasculli RM, et al. Safe resumption of electroconvulsive therapy (ECT) after vertebroplasty. Int J Geriatr Psychiatry 2012; 27:984.</a></li><li><a class="nounderline abstract_t">Eikermann M, Hunkemöller I, Peine L, et al. Optimal rocuronium dose for intubation during inhalation induction with sevoflurane in children. Br J Anaesth 2002; 89:277.</a></li><li><a class="nounderline abstract_t">Eikermann M, Renzing-Köhler K, Peters J. Probability of acceptable intubation conditions with low dose rocuronium during light sevoflurane anaesthesia in children. Acta Anaesthesiol Scand 2001; 45:1036.</a></li><li><a class="nounderline abstract_t">Beale MD, Kellner CH, Lemert R, et al. Skeletal muscle relaxation in patients undergoing electroconvulsive therapy. Anesthesiology 1994; 80:957.</a></li><li><a class="nounderline abstract_t">Mirzakhani H, Welch CA, Eikermann M, Nozari A. Neuromuscular blocking agents for electroconvulsive therapy: a systematic review. Acta Anaesthesiol Scand 2012; 56:3.</a></li><li><a class="nounderline abstract_t">Naguib M, Brull SJ, Kopman AF, et al. Consensus Statement on Perioperative Use of Neuromuscular Monitoring. Anesth Analg 2018; 127:71.</a></li><li><a class="nounderline abstract_t">Kadoi Y, Hoshi H, Nishida A, Saito S. Comparison of recovery times from rocuronium-induced muscle relaxation after reversal with three different doses of sugammadex and succinylcholine during electroconvulsive therapy. J Anesth 2011; 25:855.</a></li><li><a class="nounderline abstract_t">Saricicek V, Sahin L, Bulbul F, et al. Does rocuronium-sugammadex reduce myalgia and headache after electroconvulsive therapy in patients with major depression? J ECT 2014; 30:30.</a></li><li><a class="nounderline abstract_t">Ledowski T. Sugammadex: what do we know and what do we still need to know? A review of the recent (2013 to 2014) literature. Anaesth Intensive Care 2015; 43:14.</a></li><li><a class="nounderline abstract_t">Minneman SA. A history of oral protection for the ECT patient: past, present, and future. Convuls Ther 1995; 11:94.</a></li><li><a class="nounderline abstract_t">McCall WV, Minneman SA, Minneman SA, et al. Dental Pathology in ECT Patients Prior to Treatment. Convuls Ther 1992; 8:19.</a></li><li><a class="nounderline abstract_t">Kiran S, Bala R, Singh T. Dental protection during modified electroconvulsive therapy using roll-gauze mouth gag. J ECT 2009; 25:74.</a></li><li><a class="nounderline abstract_t">Choukalas CG, Walter J, Glick D, et al. Mask ventilation, hypocapnia, and seizure duration in electroconvulsive therapy. J Clin Anesth 2010; 22:415.</a></li><li><a class="nounderline abstract_t">Bryson EO, Hermida AP, Kellner CH. Should the laryngeal mask airway play a role in electroconvulsive therapy? Rev Psiquiatr Salud Ment 2017; 10:126.</a></li><li><a class="nounderline abstract_t">Nishihara F, Ohkawa M, Hiraoka H, et al. Benefits of the laryngeal mask for airway management during electroconvulsive therapy. J ECT 2003; 19:211.</a></li><li><a class="nounderline abstract_t">Koyama Y, Tsuzaki K, Suzuki T, et al. Prevention of Oxygen Desaturation in Morbidly Obese Patients During Electroconvulsive Therapy: A Narrative Review. J ECT 2020; 36:161.</a></li><li><a class="nounderline abstract_t">Bergsholm P, Gran L, Bleie H. Seizure duration in unilateral electroconvulsive therapy. The effect of hypocapnia induced by hyperventilation and the effect of ventilation with oxygen. Acta Psychiatr Scand 1984; 69:121.</a></li><li><a class="nounderline abstract_t">Aksay SS, Bumb JM, Janke C, et al. New evidence for seizure quality improvement by hyperoxia and mild hypocapnia. J ECT 2014; 30:287.</a></li><li><a class="nounderline abstract_t">Haeck M, Gillmann B, Janouschek H, Grözinger M. Electroconvulsive therapy can benefit from controlled hyperventilation using a laryngeal mask. Eur Arch Psychiatry Clin Neurosci 2011; 261 Suppl 2:S172.</a></li><li><a class="nounderline abstract_t">Crawford CD, Butler P, Froese A. Arterial PaO2 and PaCO2 influence seizure duration in dogs receiving electroconvulsive therapy. Can J Anaesth 1987; 34:437.</a></li><li><a class="nounderline abstract_t">Chater SN, Simpson KH. Effect of passive hyperventilation on seizure duration in patients undergoing electroconvulsive therapy. Br J Anaesth 1988; 60:70.</a></li><li><a class="nounderline abstract_t">Räsänen J, Martin DJ, Downs JB, Hodges MR. Oxygen supplementation during electroconvulsive therapy. Br J Anaesth 1988; 61:593.</a></li><li><a class="nounderline abstract_t">Lew JK, Eastley RJ, Hanning CD. Oxygenation during electroconvulsive therapy. A comparison of two anaesthetic techniques. Anaesthesia 1986; 41:1092.</a></li><li><a class="nounderline abstract_t">Swindells SR, Simpson KH. Oxygen saturation during electroconvulsive therapy. Br J Psychiatry 1987; 150:695.</a></li><li><a class="nounderline abstract_t">Buj-Alvarez I, Pifarré J, Marco G, et al. Can the laryngeal mask play a role in electroconvulsive treatment? A pilot study. Rev Psiquiatr Salud Ment 2016; 9:203.</a></li><li><a class="nounderline abstract_t">Mayur P, Bray A, Fernandes J, et al. Impact of hyperventilation on stimulus efficiency during the early phase of an electroconvulsive therapy course: a randomized double-blind study. J ECT 2010; 26:91.</a></li><li><a class="nounderline abstract_t">Laffey JG, Kavanagh BP. Hypocapnia. N Engl J Med 2002; 347:43.</a></li><li><a class="nounderline abstract_t">Saito S, Kadoi Y, Nihishara F, et al. End-tidal carbon dioxide monitoring stabilized hemodynamic changes during ECT. J ECT 2003; 19:26.</a></li><li><a class="nounderline abstract_t">Saito S. Anesthesia management for electroconvulsive therapy: hemodynamic and respiratory management. J Anesth 2005; 19:142.</a></li><li><a class="nounderline abstract_t">Nosovitch MA, Johnson JO, Tobias JD. Noninvasive intraoperative monitoring of carbon dioxide in children: endtidal versus transcutaneous techniques. Paediatr Anaesth 2002; 12:48.</a></li><li><a class="nounderline abstract_t">Mizen L, Morton C, Scott A. The cardiovascular safety of the empirical measurement of the seizure threshold in electroconvulsive therapy. BJPsych Bull 2015; 39:14.</a></li><li><a class="nounderline abstract_t">Bhat SK, Acosta D, Swartz CM. Postictal asystole during ECT. J ECT 2002; 18:103.</a></li><li><a class="nounderline abstract_t">Bryson EO, Kellner CH, Ahle GM, Liebman LS. Asystole during electroconvulsive therapy. J ECT 2014; 30:259.</a></li><li><a class="nounderline abstract_t">Kaufman KR. Asystole with electroconvulsive therapy. J Intern Med 1994; 235:275.</a></li><li><a class="nounderline abstract_t">Wells DG, Zelcer J, Treadrae C. ECT-induced asystole from a sub-convulsive shock. Anaesth Intensive Care 1988; 16:368.</a></li><li><a class="nounderline abstract_t">Stewart PT, Loo CK, MacPherson R, Hadzi-Pavlovic D. The effect of electrode placement and pulsewidth on asystole and bradycardia during the electroconvulsive therapy stimulus. Int J Neuropsychopharmacol 2011; 14:585.</a></li><li><a class="nounderline abstract_t">Burd J, Kettl P. Incidence of asystole in electroconvulsive therapy in elderly patients. Am J Geriatr Psychiatry 1998; 6:203.</a></li><li><a class="nounderline abstract_t">Wells DG, Davies GG. Hemodynamic changes associated with electroconvulsive therapy. Anesth Analg 1987; 66:1193.</a></li><li><a class="nounderline abstract_t">Duma A, Maleczek M, Panjikaran B, et al. Major Adverse Cardiac Events and Mortality Associated with Electroconvulsive Therapy: A Systematic Review and Meta-analysis. Anesthesiology 2019; 130:83.</a></li><li><a class="nounderline abstract_t">Boere E, Birkenhäger TK, Groenland TH, van den Broek WW. Beta-blocking agents during electroconvulsive therapy: a review. Br J Anaesth 2014; 113:43.</a></li><li><a class="nounderline abstract_t">Blumberger DM, Seitz DP, Herrmann N, et al. Low medical morbidity and mortality after acute courses of electroconvulsive therapy in a population-based sample. Acta Psychiatr Scand 2017; 136:583.</a></li><li><a class="nounderline abstract_t">Tørring N, Sanghani SN, Petrides G, et al. The mortality rate of electroconvulsive therapy: a systematic review and pooled analysis. Acta Psychiatr Scand 2017; 135:388.</a></li><li><a class="nounderline abstract_t">Dinwiddie SH, Huo D, Gottlieb O. The course of myalgia and headache after electroconvulsive therapy. J ECT 2010; 26:116.</a></li><li><a class="nounderline abstract_t">Oms A, Miro E, Rojo JE. Sumatriptan was effective in electroconvulsive therapy (ECT) headache. Anesthesiology 1998; 89:1291.</a></li><li><a class="nounderline abstract_t">DeBattista C, Mueller K. Sumatriptan prophylaxis for postelectroconvulsive therapy headaches. Headache 1995; 35:502.</a></li><li><a class="nounderline abstract_t">Kertesz DP, Trabekin O, Vanetik MS. Headache treatment after electroconvulsive treatment: a single-blinded trial comparator between eletriptan and paracetamol. J ECT 2015; 31:105.</a></li><li><a class="nounderline abstract_t">Kramer BA, Kadar AG, Clark K. Use of the Neuro-Wrap system for severe post-electroconvulsive therapy headaches. J ECT 2008; 24:152.</a></li><li><a class="nounderline abstract_t">Li TC, Shiah IS, Sun CJ, et al. Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature. J ECT 2011; 27:165.</a></li><li><a class="nounderline abstract_t">Swartz CM. Electroconvulsive therapy emergence agitation and succinylcholine dose. J Nerv Ment Dis 1990; 178:455.</a></li><li><a class="nounderline abstract_t">Augoustides JG, Greenblatt E, Abbas MA, et al. Clinical approach to agitation after electroconvulsive therapy: a case report and literature review. J ECT 2002; 18:213.</a></li><li><a class="nounderline abstract_t">Logan CJ, Stewart JT. Treatment of post-electroconvulsive therapy delirium and agitation with donepezil. J ECT 2007; 23:28.</a></li><li><a class="nounderline abstract_t">Tzabazis A, Schmitt HJ, Ihmsen H, et al. Postictal agitation after electroconvulsive therapy: incidence, severity, and propofol as a treatment option. J ECT 2013; 29:189.</a></li><li><a class="nounderline abstract_t">Bryson EO, Popeo DM, Kellner CH. Electroconvulsive therapy (ECT) after pulmonary edema. J ECT 2012; 28:e25.</a></li><li><a class="nounderline abstract_t">Sargent P, Reeves J. Pulmonary edema after electroconvulsive therapy. J ECT 2008; 24:283.</a></li><li><a class="nounderline abstract_t">Price JW, Price JR, Perry TL. Excessive hypertension and pulmonary edema after electroconvulsive therapy. J ECT 2005; 21:174.</a></li><li><a class="nounderline abstract_t">Fryml L, Fox J, Manett AJ, et al. Neurogenic Pulmonary Edema Complicating ECT. J ECT 2018; 34:78.</a></li><li><a class="nounderline abstract_t">Mansoor D, Trevino C, Ganzini L, Zornow M. Negative Pressure Pulmonary Edema after Electroconvulsive Therapy. J ECT 2016; 32:e2.</a></li><li><a class="nounderline abstract_t">Myers CL, Gopalka A, Glick D, et al. A case of negative-pressure pulmonary edema after electroconvulsive therapy. J ECT 2007; 23:281.</a></li><li><a class="nounderline abstract_t">Duma A, Pal S, Johnston J, et al. High-sensitivity Cardiac Troponin Elevation after Electroconvulsive Therapy: A Prospective, Observational Cohort Study. Anesthesiology 2017; 126:643.</a></li><li><a class="nounderline abstract_t">Martinez MW, Rasmussen KG, Mueller PS, Jaffe AS. Troponin elevations after electroconvulsive therapy: the need for caution. Am J Med 2011; 124:229.</a></li><li><a class="nounderline abstract_t">O'Flaherty D, Husain MM, Moore M, et al. Circulatory responses during electroconvulsive therapy. The comparative effects of placebo, esmolol and nitroglycerin. Anaesthesia 1992; 47:563.</a></li><li><a class="nounderline abstract_t">Medved S, Ostojić Z, Jurin H, Medved V. Takotsubo cardiomyopathy after the first electroconvulsive therapy regardless of adjuvant beta-blocker use: a case report and literature review. Croat Med J 2018; 59:307.</a></li><li><a class="nounderline abstract_t">Sharp RP, Welch EB. Takotsubo cardiomyopathy as a complication of electroconvulsive therapy. Ann Pharmacother 2011; 45:1559.</a></li><li><a class="nounderline abstract_t">Felkel WC 2nd, Wagner G, Kimball J, et al. Tardive seizure with postictal aphasia: a case report. J ECT 2012; 28:180.</a></li><li><a class="nounderline abstract_t">Balki M, Castro C, Ananthanarayan C. Status epilepticus after electroconvulsive therapy in a pregnant patient. Int J Obstet Anesth 2006; 15:325.</a></li><li><a class="nounderline abstract_t">Glénisson L, Auriacombe M, Fernandez T, et al. [Adverse seizure reactions after electroconvulsive therapy. Study of personal cases and review of the literature]. Encephale 1998; 24:1.</a></li><li><a class="nounderline abstract_t">Saito T, Nakamura M, Watari M, Isse K. Tardive seizure and antibiotics: case reports and review of the literature. J ECT 2008; 24:275.</a></li><li><a class="nounderline abstract_t">Kisa C, Yildirim SG, Aydemir C, et al. Prolonged electroconvulsive therapy seizure in a patient taking ciprofloxacin. J ECT 2005; 21:43.</a></li><li><a class="nounderline abstract_t">Aftab A, VanDercar A, Alkhachroum A, et al. Nonconvulsive Status Epilepticus After Electroconvulsive Therapy: A Review of Literature. Psychosomatics 2018; 59:36.</a></li><li><a class="nounderline abstract_t">Kurani AP, Kellner CH, Turbin RE, et al. Transient visual loss after right unilateral ECT. J ECT 2005; 21:186.</a></li><li><a class="nounderline abstract_t">Liff JM, Bryson EO, Maloutas E, et al. Transient hemiparesis (Todd's paralysis) after electroconvulsive therapy (ECT) in a patient with major depressive disorder. J ECT 2013; 29:247.</a></li><li><a class="nounderline abstract_t">Bruce BB, Henry ME, Greer DM. Ischemic stroke after electroconvulsive therapy. J ECT 2006; 22:150.</a></li><li><a class="nounderline abstract_t">Gugger JJ, Dunn LE. Subarachnoid Hemorrhage in the Setting of Electroconvulsive Therapy in a Patient With an Unsecured Cerebral Aneurysm: A Case Report and Review of the Literature. J ECT 2019; 35:212.</a></li><li><a class="nounderline abstract_t">Wilkinson ST, Helgeson L, Ostroff RB. Electroconvulsive therapy and cerebral aneurysms. J ECT 2014; 30:e47.</a></li><li><a class="nounderline abstract_t">Limoncelli J, Marino T, Smetana R, et al. General Anesthesia Recommendations for Electroconvulsive Therapy During the Coronavirus Disease 2019 Pandemic. J ECT 2020; 36:152.</a></li><li><a class="nounderline abstract_t">Bryson EO, Aloysi AS. A strategy for management of ECT patients during the COVID-19 pandemic. J ECT 2020.</a></li><li><a class="nounderline abstract_t">Hartnett S, Rex S, Sienaert P. Asystole During Electroconvulsive Therapy: Does Electrode Placement Matter? A Systematic Review. J ECT 2023; 39:3.</a></li></ol></div><div id="topicVersionRevision">Topic 102832 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.asahq.org/Search.aspx?q=standards+basic+anesthetic+monitoring" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : American Society of Anesthesiologists. Standards for Basic Anesthetic Monitoring. www.asahq.org/Search.aspx?q=standards+basic+anesthetic+monitoring (Accessed on March 29, 2016).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.asahq.org/standards-and-guidelines" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : https://www.asahq.org/standards-and-guidelines (Accessed on May 21, 2019).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28430533" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : New directions in the rational design of electrical and magnetic seizure therapies: individualized Low Amplitude Seizure Therapy (iLAST) and Magnetic Seizure Therapy (MST).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27339618" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : An overview on clinical aspects in magnetic seizure therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27339618" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : An overview on clinical aspects in magnetic seizure therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28277323" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Individualized Anesthetic Management for Patients Undergoing Electroconvulsive Therapy: A Review of Current Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19701065" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27327556" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A Systematic Review of the Safety of Electroconvulsive Therapy Use During the First Trimester of Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28489640" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Little Black Boxes: Noncardiac Implantable Electronic Medical Devices and Their Anesthetic and Surgical Implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24553318" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Safety of electroconvulsive therapy in the presence of cranial metallic objects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30407933" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The Safety of Electroconvulsive Therapy in Patients With Implanted Deep Brain Stimulators: A Review of the Literature and Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12009429" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Antidepressants inhibit human acetylcholinesterase and butyrylcholinesterase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28345306" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8846618" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22537574" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11351116" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Possible serotonin syndrome in association with 5-HT(3) antagonist agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15784664" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The serotonin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17381671" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Serotonin syndrome caused by interaction between citalopram and fentanyl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16051647" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10221364" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The serotonin syndrome and its treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10221364" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The serotonin syndrome and its treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10221364" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The serotonin syndrome and its treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16127306" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The safety of electroconvulsive therapy and lithium in combination: a case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1267214" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Potentiation of succinylcholine neuromuscular blockade by lithium carbonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/835845" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Lithium carbonate and neuromuscular blocking agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17548985" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Anticonvulsants during electroconvulsive therapy: review and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27385853" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of age and anticonvulsants on seizure threshold during bilateral electroconvulsive therapy with brief-pulse stimulus: A chart-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27668943" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Concomitant Anticonvulsants With Bitemporal Electroconvulsive Therapy: A Randomized Controlled Trial With Clinical and Neurobiological Application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24623978" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Influence of valproate on the required dose of propofol for anesthesia during electroconvulsive therapy of bipolar affective disorder patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11945107" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Interactions between psychotropics, anaesthetics and electroconvulsive therapy: implications for drug choice and patient management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21821508" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Perioperative exacerbation of valproic acid-associated hyperammonemia: a clinical and genetic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16861142" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29696528" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Case Report: Successful Use of the Combination of Electroconvulsive Therapy and Clozapine in Treating Treatment-Resistant Schizophrenia and Catatonia in an Adult with Intellectual Disability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25157964" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10460810" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9673859" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Neuroleptic malignant syndrome. Recognition, prevention and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29061403" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11358771" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1702937" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Insights into the structure and function of GABA-benzodiazepine receptors: ion channels and psychiatry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2375437" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Evidence for less improvement in depression in patients taking benzodiazepines during unilateral ECT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30720551" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : How Much Do Benzodiazepines Matter for Electroconvulsive Therapy in Patients With Major Depression?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27514303" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adverse Effects of Electroconvulsive Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11126187" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Side effects of electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8200790" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Headache and electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32205737" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The Incidence of Post-Electroconvulsive Therapy Headache: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28754173" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A randomized, double-blind, placebo-controlled trial on the role of preemptive analgesia with acetaminophen [paracetamol] in reducing headache following electroconvulsive therapy [ECT].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12755658" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pretreatment with ibuprofen to prevent electroconvulsive therapy-induced headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9010653" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28862317" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Is prolongation of corrected QT interval associated with seizures induced by electroconvulsive therapy reduced by atropine sulfate?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24755728" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effect of atropine dose on heart rate during electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30504059" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Electro convulsive therapy: Modification of its effect on the autonomic nervous system using anti-cholinergic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25788781" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Incidence and risk factors for oxygen desaturation during recovery from modified electroconvulsive therapy: A prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33752777" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The effect of anaesthetic dose on response and remission in electroconvulsive therapy for major depressive disorder: nationwide register-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22914634" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Methohexital and succinylcholine dosing for electroconvulsive therapy (ECT): actual versus ideal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8010457" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Anesthesia for electroconvulsive therapy: effects of propofol and methohexital on seizure activity and recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18090696" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Propofol and methohexital as anesthetic agents for electroconvulsive therapy: a randomized, double-blind comparison of electroconvulsive therapy seizure quality, therapeutic efficacy, and cognitive performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2180345" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pro- and anticonvulsant effects of anesthetics (Part II)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22330701" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A within-subject comparison of propofol and methohexital anesthesia for electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26806849" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A Bayesian framework systematic review and meta-analysis of anesthetic agents effectiveness/tolerability profile in electroconvulsive therapy for major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24723301" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Different regimens of intravenous sedatives or hypnotics for electroconvulsive therapy (ECT) in adult patients with depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19092676" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Comparison of propofol and thiopental as anesthetic agents for electroconvulsive therapy: a randomized, blinded comparison of seizure duration, stimulus charge, clinical effect, and cognitive side effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23399487" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Comparison of methohexital and etomidate as anesthetic agents for electroconvulsive therapy in affective and psychotic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9144065" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A review of etomidate for rapid sequence intubation in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16531603" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Intubating conditions and hemodynamic effects of etomidate for rapid sequence intubation in the emergency department: an observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25634566" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Evaluation of Etomidate for Seizure Duration in Electroconvulsive Therapy: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25010029" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Etomidate is still a valid anesthetic for electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28448702" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23876043" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : New paradigms for treatment-resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23726151" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12556568" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24388729" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24091902" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29700801" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Ketamine-based anesthesia improves electroconvulsive therapy outcomes: a randomized-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22858219" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28385704" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Adjunctive ketamine in electroconvulsive therapy: updated systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29794567" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Ketamine and electroconvulsive therapy: so happy together?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31725054" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Effects of Ketamine Anesthesia on Efficacy, Tolerability, Seizure Response, and Neurocognitive Outcomes in Electroconvulsive Therapy: A Comprehensive Meta-analysis of Double-Blind Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31913927" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Effects of Low-Dose Ketamine on the Antidepressant Efficacy and Suicidal Ideations in Patients Undergoing Electroconvulsive Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30852364" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Adjunctive ketamine and electroconvulsive therapy for major depressive disorder: A meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23475029" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26440233" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Impact comparison of ketamine and sodium thiopental on anesthesia during electroconvulsive therapy in major depression patients with drug-resistant; a double-blind randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27008330" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Ketamine Anesthesia, Efficacy of Electroconvulsive Therapy, and Cognitive Functions in Treatment-Resistant Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22847373" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25085036" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effects of sevoflurane or ketamine on the QTc interval during electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22623080" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Ketofol in electroconvulsive therapy anesthesia: two stones for one bird.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22622291" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28263242" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Dexmedetomidine Combined With Intravenous Anesthetics in Electroconvulsive Therapy: A Meta-analysis and Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29127492" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Effect of dexmedetomidine for attenuation of propofol injection pain in electroconvulsive therapy: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29085099" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Effectiveness of dexmedetomidine as premedication prior to electroconvulsive therapy, a Randomized controlled cross over study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28074804" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Outcome of four pretreatment regimes on hemodynamics during electroconvulsive therapy: A double-blind randomized controlled crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28601627" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Effects of small-dose dexmedetomidine on hyperdynamic responses to electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28579785" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Dexmedetomidine for the management of postictal agitation after electroconvulsive therapy with S-ketamine anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23519216" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Treatment-resistant postictal agitation after electroconvulsive therapy (ECT) controlled with dexmedetomidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19710618" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Dexmedetomidine and the successful management of electroconvulsive therapy postictal agitation: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31688331" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Preventive effect of dexmedetomidine on postictal delirium after electroconvulsive therapy: A randomised controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21673589" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Remifentanil: a review of its use in electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18772705" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Effects of the addition of remifentanil to propofol anesthesia on seizure length and postictal suppression index in electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16095445" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Effects of remifentanil and alfentanil on seizure duration, stimulus amplitudes and recovery parameters during ECT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11472282" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Effects of combined methohexitone-remifentanil anaesthesia in electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27029661" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The effect of adjuvant remifentanil with propofol or thiopentone on seizure quality during electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26822480" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28235531" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Effects of the concurrent use of a reduced dose of propofol with divided supplemental remifentanil and moderate hyperventilation on duration and morphology of electroconvulsive therapy-induced electroencephalographic seizure activity: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15591854" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : A retrospective comparison of remifentanil versus methohexital for anesthesia in electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27038445" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Does remifentanil improve ECT seizure quality?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30442255" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Remifentanil as an adjunct to anaesthesia for electroconvulsive therapy fails to confer long-term benefits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16301885" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The clinical utility of inhalational anesthesia with sevoflurane in electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8706599" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657775" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : The comparative effects of sevoflurane and methohexital for electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15905753" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Sevoflurane as an alternative anaesthetic for electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34352164" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Anesthesia for Electroconvulsive Therapy: A Niche Role for Sevoflurane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11575338" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Comparison of pattern of breathing with other measures of induction of anaesthesia, using propofol, methohexital, and sevoflurane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17124640" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : ECT anesthesia: the lighter the better?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11973199" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Pre-ictal bispectral index has a positive correlation with seizure duration during electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15041593" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Bispectral index as an indicator of seizure inducibility in electroconvulsive therapy under thiopental anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15535490" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Adjustment of anaesthesia depth using bispectral index prolongs seizure duration in electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20562643" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : The bispectral electroencephalogram during modified electroconvulsive therapy under propofol anesthesia: relation with seizure duration and awakening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23359338" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Bispectral index monitoring and seizure quality optimization in electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28640168" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Degree of Postictal Suppression Depends on Seizure Induction Time in Magnetic Seizure Therapy and Electroconvulsive Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31151038" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The effectiveness of BIS monitoring during electro-convulsive therapy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15591328" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Comparative effects of ketamine on Bispectral Index and spectral entropy of the electroencephalogram under sevoflurane anaesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22330703" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Effect of a course of electroconvulsive therapy on interictal bispectral index values: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26967896" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Minimum Effective Doses of Succinylcholine and Rocuronium During Electroconvulsive Therapy: A Prospective, Randomized, Crossover Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29504412" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Extreme variability in succinylcholine dose for muscle relaxation in electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22886870" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Safe resumption of electroconvulsive therapy (ECT) after vertebroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12378667" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Optimal rocuronium dose for intubation during inhalation induction with sevoflurane in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11576058" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Probability of acceptable intubation conditions with low dose rocuronium during light sevoflurane anaesthesia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7848406" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Skeletal muscle relaxation in patients undergoing electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22092267" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Neuromuscular blocking agents for electroconvulsive therapy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29200077" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Consensus Statement on Perioperative Use of Neuromuscular Monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21947754" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Comparison of recovery times from rocuronium-induced muscle relaxation after reversal with three different doses of sugammadex and succinylcholine during electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23812022" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Does rocuronium-sugammadex reduce myalgia and headache after electroconvulsive therapy in patients with major depression?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25579285" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Sugammadex: what do we know and what do we still need to know? A review of the recent (2013 to 2014) literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7552060" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : A history of oral protection for the ECT patient: past, present, and future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11941145" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Dental Pathology in ECT Patients Prior to Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19258864" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Dental protection during modified electroconvulsive therapy using roll-gauze mouth gag.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20868961" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Mask ventilation, hypocapnia, and seizure duration in electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26897253" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Should the laryngeal mask airway play a role in electroconvulsive therapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657773" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Benefits of the laryngeal mask for airway management during electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32040021" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Prevention of Oxygen Desaturation in Morbidly Obese Patients During Electroconvulsive Therapy: A Narrative Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6422704" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Seizure duration in unilateral electroconvulsive therapy. The effect of hypocapnia induced by hyperventilation and the effect of ventilation with oxygen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24625713" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : New evidence for seizure quality improvement by hyperoxia and mild hypocapnia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21901267" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Electroconvulsive therapy can benefit from controlled hyperventilation using a laryngeal mask.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3664909" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Arterial PaO2 and PaCO2 influence seizure duration in dogs receiving electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3122811" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Effect of passive hyperventilation on seizure duration in patients undergoing electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3207530" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Oxygen supplementation during electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3789366" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Oxygenation during electroconvulsive therapy. A comparison of two anaesthetic techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3651707" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Oxygen saturation during electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26614273" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Can the laryngeal mask play a role in electroconvulsive treatment? A pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20514695" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Impact of hyperventilation on stimulus efficiency during the early phase of an electroconvulsive therapy course: a randomized double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12097540" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Hypocapnia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12621274" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : End-tidal carbon dioxide monitoring stabilized hemodynamic changes during ECT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15875132" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Anesthesia management for electroconvulsive therapy: hemodynamic and respiratory management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849575" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Noninvasive intraoperative monitoring of carbon dioxide in children: endtidal versus transcutaneous techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26191418" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : The cardiovascular safety of the empirical measurement of the seizure threshold in electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12195140" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Postictal asystole during ECT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25010033" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Asystole during electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8120525" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Asystole with electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3056091" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : ECT-induced asystole from a sub-convulsive shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21205432" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : The effect of electrode placement and pulsewidth on asystole and bradycardia during the electroconvulsive therapy stimulus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9659953" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Incidence of asystole in electroconvulsive therapy in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3662067" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Hemodynamic changes associated with electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30557212" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Major Adverse Cardiac Events and Mortality Associated with Electroconvulsive Therapy: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24942714" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Beta-blocking agents during electroconvulsive therapy: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28922451" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Low medical morbidity and mortality after acute courses of electroconvulsive therapy in a population-based sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28332236" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : The mortality rate of electroconvulsive therapy: a systematic review and pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19710619" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : The course of myalgia and headache after electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9822034" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Sumatriptan was effective in electroconvulsive therapy (ECT) headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7591748" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Sumatriptan prophylaxis for postelectroconvulsive therapy headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25181019" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Headache treatment after electroconvulsive treatment: a single-blinded trial comparator between eletriptan and paracetamol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18580561" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Use of the Neuro-Wrap system for severe post-electroconvulsive therapy headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21602639" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2366059" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Electroconvulsive therapy emergence agitation and succinylcholine dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12468998" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Clinical approach to agitation after electroconvulsive therapy: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17435571" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Treatment of post-electroconvulsive therapy delirium and agitation with donepezil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23792779" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Postictal agitation after electroconvulsive therapy: incidence, severity, and propofol as a treatment option.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22622302" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Electroconvulsive therapy (ECT) after pulmonary edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18617864" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Pulmonary edema after electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16127308" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Excessive hypertension and pulmonary edema after electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29166318" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Neurogenic Pulmonary Edema Complicating ECT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26579637" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Negative Pressure Pulmonary Edema after Electroconvulsive Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18090704" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : A case of negative-pressure pulmonary edema after electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28166110" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : High-sensitivity Cardiac Troponin Elevation after Electroconvulsive Therapy: A Prospective, Observational Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21396506" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Troponin elevations after electroconvulsive therapy: the need for caution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1352662" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Circulatory responses during electroconvulsive therapy. The comparative effects of placebo, esmolol and nitroglycerin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30610773" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Takotsubo cardiomyopathy after the first electroconvulsive therapy regardless of adjuvant beta-blocker use: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22116995" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Takotsubo cardiomyopathy as a complication of electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22573186" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Tardive seizure with postictal aphasia: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16774832" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Status epilepticus after electroconvulsive therapy in a pregnant patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9559297" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : [Adverse seizure reactions after electroconvulsive therapy. Study of personal cases and review of the literature].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18580694" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Tardive seizure and antibiotics: case reports and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15791178" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Prolonged electroconvulsive therapy seizure in a patient taking ciprofloxacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28802513" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Nonconvulsive Status Epilepticus After Electroconvulsive Therapy: A Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16127312" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Transient visual loss after right unilateral ECT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23291704" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Transient hemiparesis (Todd's paralysis) after electroconvulsive therapy (ECT) in a patient with major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16801834" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Ischemic stroke after electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30720550" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Subarachnoid Hemorrhage in the Setting of Electroconvulsive Therapy in a Patient With an Unsecured Cerebral Aneurysm: A Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25010028" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Electroconvulsive therapy and cerebral aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32483035" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : General Anesthesia Recommendations for Electroconvulsive Therapy During the Coronavirus Disease 2019 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32404699" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : A strategy for management of ECT patients during the COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35700970" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Asystole During Electroconvulsive Therapy: Does Electrode Placement Matter? A Systematic Review.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
